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ZUSAMMENFASSUNG
Braunes Fettgewebe (BAT) hat in den letzten Jahrzehnten zur Bekämp-fung von Fettleibigkeit und ihrer Folgeerkrankungen als therapeutisches
Mittel stark an Aufmerksamkeit gewonnen. Sowohl in Nagern als auch
in Menschen schützt aktiviertes BAT mittels Steigerung des Energieum-
satzes vor Diät-induzierter Fettleibigkeit und der zugehörigen Beeinträchti-
gung des Glukose-Metabolismus. Interessanterweise können BAT-ähnliche
Eigenschaften auch in Vorläuferzellen der quergestreiften Muskulatur her-
vorgerufen werden, da diese beiden Gewebe einer gemeinsamen Zelllinie
entstammen. Es konnte nachgewiesen werden, dass Differenzierung and
Funktion von BAT durch nicht-kodierende RNA-Netzwerke kontrolliert wird.
Insbesondere sind verschiedenste microRNAs (miRNAs) dazu in der Lage,
sowohl BAT-Homöostase als auch die Zelllinien-Entscheidung zwischen BAT
und quergestreifter Muskulatur zu beeinflussen.
In dieser Studie zeigen wir eine neue miR-328-Bace1 Achse auf, welche
an metabolischer Homöostase beteiligt ist, indem sie die Differenzierung
und Aktivierung brauner Fettzellen fördert. Wir konnten nachweisen, dass
die Expression von miR-328 mit BAT-Aktivität korreliert und zudem in
vitro die Differenzierung brauner Fettzellen - unter Benachteiligung von
Muskelzell-Entwicklung - begünstigt. Dieser Vorgang wird veranlasst mittels
der Inhibition durch die miRNA von der β-Sekretase BACE1, einer Protease,
welche für ihre schädliche Rolle in Alzheimer-Entwicklung bekannt ist. In
der Tat konnten wir nachweisen, dass sich BACE1 antagonistisch zu miR-328
verhält. Sowohl Bace1 Knock-Down als auch Knock-Out führten zu einem
pro-adipogenen Phänotyp in braunen Fettzellen und sogar Muskelzellen.
Darüber hinaus konnte dem konditionierten Medium von Bace1 Knock-Out-
Myoblasten eine parakrine Wirkung zugewiesen werden, da es das adipo-
gene Potenzial von Wildtyp-Myoblasten steigerte. Komplementäre Proteom-
Analysen ermittelten anschließend potenzielle BACE1-Substrate, welche in
diesen Vorgang verwickelt sein könnten. Von besonderem Interesse wurde
hierbei AOC3 als vermeintliches BACE1-Substrat identifiziert, ein entzün-
dungsförderndes Transmembran-Protein, welches im Zusammenhang mit
Typ-2-Diabetes steht. Die lösliche Form des Proteins, sAOC3, ermöglicht
diesem parakrine und endokrine Funktionen. Dieser Mechanismus könnte
für die vorteilhaften metabolischen Effekte durch BACE1-Inhibition ver-
xi
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antwortlich sein, welche wir in fettleibigen Mäusen beobachten konnten.
Tatsächlich konnten wir zeigen, dass reduzierte BACE1-Aktivität, welche
bekanntermaßen die Pathophysiologie der Alzheimer-Krankheit mindert,
auch die Energie-Homöostase des gesamten Körpers verbesserte, indem sie
verminderte Gewichtszunahme und einen günstigeren Glukose-Stoffwechsel
hervorrief. Des Weiteren führte BACE1-Inhibition zu einer erhöhten BAT-
Marker-Expression in braunem Fett und gleichzeitig zu einer globalen Ver-
minderung von Differenzierungs-Markern der quergestreiften Muskulatur.
Zusammengefasst stellen BACE1 und dessen Substrate, eventuell einschließ-
lich AOC3, vielversprechende Ansätze zur Bekämpfung von Fettleibigkeit,
der Alzeimer-Krankheit und deren Folgeerkrankungen dar. Somit erweitert
diese Arbeit das Anwendungsgebiet von BACE1 - über Alzheimer-Krankheit
hinaus - zu BAT und Stoffwechselregulation.
xii
SUMMARY
In the last decades brown adipose tissue (BAT) rose to attention as thera-peutic target to counteract obesity and its related diseases. In both rodents
and humans, activated BAT protects from diet-induced obesity and the asso-
ciated deterioration of glucose metabolism via enhancing energy expenditure.
Interestingly, BAT-related features can also be promoted in skeletal muscle
(SM) progenitor cells due to the common cell lineage that these tissue share.
Differentiation and function of BAT has been shown to be under control of
noncoding RNA networks. In particular, various microRNAs (miRNAs) are
able to drive both brown fat homeostasis and BAT/SM cell fate regulation.
Here we show a novel miR-328–Bace1 axis involved in metabolic homeostasis
through a mechanism that promotes brown adipocyte differentiation and
activation. We found miR-328 expression to correlate to BAT activity and to
promote brown adipogenesis to the detriment of myogenesis in vitro. This pro-
cess is dependent on the inhibition by the miRNA of the β-secretase BACE1,
a protease known for its detrimental role in Alzheimer’s disease (AD). We
could show this protein to act antagonistically to miR-328. Indeed, both
knock-down and knock-out of Bace1 resulted in a pro-adipogenic phenotype
in both brown adipogenic and even myogenic cell lines. Moreover, condi-
tioned medium from Bace1 knock-out myoblasts revealed paracrine effects by
stimulating the adipogenic potential of wild-type myoblasts. Complementary
proteomic analyses determined potential substrates of BACE1 involved in
this process. In particular, AOC3, a pro-inflammatory, type 2 diabetes-related
transmembrane protein, was identified as a putative BACE1 target, with po-
tential paracrine and endocrine functions due to its soluble form sAOC3. This
mechanism could be responsible for the beneficial metabolic effects of BACE1
inhibition observed in obese mice. In fact, we showed that diminished BACE1
activity, known to reduce the pathophysiology of AD, enhanced whole-body
homeostasis, leading to decreased body weight gain and ameliorated glucose
metabolism. BACE1 inhibition was furthermore associated with increased
BAT marker expression in the adipose tissue and a global decrease in SM-
associated differentiation pathways.
Taken together, BACE1 and its substrates, potentially including AOC3, are
promising therapeutic targets against obesity, AD and their sequelae. This
warrants the broadening of the scientific scope for BACE1 investigation
beyond AD and towards BAT and metabolism regulation.
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GRAPHIC ABSTRACT
Dicer1-miR-328-Bace1 axis ensures brown adipose tissue homeostasis
and energy metabolism in mice.
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INTRODUCTION
1.1 The obesity pandemic and associated diseases
In the last decades obesity has become a major socio-economic burden in our society,with more than 1.9 billion adults worldwide being overweight in 2014, of which over
600 million were obese [1]. The World Health Organisation (WHO) defines overweight
and obesity as abnormal or excessive fat accumulation that may impair an individual‚Äôs
health status [1]. To classify these two conditions in adults in an unbiased way, the
body mass index (BMI) is utilised. BMI is an index of weight-for-height defined as a
person’s weight in kilograms divided by the square of his height in meters (kg/m2).
The standard for body mass categorisation considers an adult with a BMI greater than
or equal to 25 as overweight and a BMI greater than or equal to 30 as obese [1]. In
recent years the obesity pandemic reached such a severe impact worldwide that in
every region, except parts of sub-Saharan Africa and Asia, overweight and obesity are
linked to more deaths than underweight [1], placing a massive burden on health systems
around the globe. This global rise in the prevalence of obesity does not only affect
adults, with more than 41 million children under the age of 5 considered overweight or
obese [1]. In rodents it has been shown that offspring obesity is dependent on maternal
impaired glucose homeostasis during lactation [2], demonstrating a transgenerational
occurrence of the metabolic syndrome. Alterations in body fat mass and abnormal fat
distribution, known as lipodystrophy, have a major impact on whole-body metabolism
and can lead to increased risk of type 2 diabetes mellitus (T2D), cardiovascular diseases,
neurodegenerative diseases, some types of cancer [3] [4] [5] and in general all-cause
mortality [6].
1
CHAPTER 1. INTRODUCTION
1.1.1 Obesity and type 2 diabetes mellitus
The main obesity-related disease is unanimously type 2 diabetes mellitus, with more
than 422 million adults affected worldwide (Data from 2014) [7]. T2D is a complex
metabolic disease characterised by defect insulin signalling and subsequently increased
levels of glucose in the serum, known as hyperglycaemia. The peptide hormone insulin
acts in a post-prandial manner as it is able to clear plasma of glucose and triacylglyce-
rols by receptor-mediated uptake into cells of peripheral organs. On a molecular level
insulin triggers glucose uptake into peripheral organs via binding to the insulin-receptor
and inducing a subsequent signalling pathway including phosphatidyl inositol 3-kinase
pathway (PI3K). The following downstream cascade includes AKT/protein kinase B
(PKB), which in its phosphorylated - and activated - form, regulates the activity of
many targets, including kinases, transcription factors and other molecules involved
in metabo-regulatory pathways [8]. Chronic activation of the insulin-receptor though
may lead to insulin-desensitisation in many organs, including liver, adipose tissue and
skeletal muscle. To compensate for the insulin resistance, pancreatic β-cells become
constitutively over-productive and may break, leading to a complete lack of endogenous
insulin secretion, which manifests in hyperglycaemia and T2D [9].
Risk factors for T2D include not only many genetic, but also epigenetic components
caused by environmental triggers such as diet, lifestyle and obesity [10]. The develop-
ment and pathophysiology of obesity and T2D are so interconnected that is difficult to
pinpoint any exclusive causes to each of them.
Although the treatment of T2D is nowadays relatively standardised and careful monitor-
ing of blood sugar levels allows many patients to live a healthy life, impairment of glucose
homeostasis can lead to serious complications throughout the body. These complications,
that include heart attack, stroke, kidney failure, leg amputation and vision loss, can lead
to premature death, making T2D a major cause of deaths worldwide with 1.5 million
deaths caused by this disease in 2012 only [7].
1.1.2 Obesity and neurodegenerative diseases
Glucose homeostasis plays a central role in regulating brain metabolism. Indeed, the
brain consumes around 25% of total body glucose despite constituting only 2% of body
weight [11]. Impairment in glucose regulation and obesity have been associated with a
higher risk of developing neurodegenerative diseases like Alzheimer’s (AD), Parkinson’s
(PD), Huntington’s diseases and multiple sclerosis [12]. Given the shared deterioration
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of glucose homeostasis in the onset both obesity and neurodegenerative diseases, a BMI
above 25 is not only considered a risk factor for the development of T2D but also for AD
and PD [13]. In fact T2D prevalence has a high epidemiological correlation with AD [14].
1.2 Alzheimer’s disease
Alzheimer’s disease is the most common among neurodegenerative diseases affectingabout 47 million people worldwide, a number which is constantly increasing [15].
The disease is defined by two pathological hallmarks: extracellular amyloid plaques and
intracellular neurofibrillary tangles. These features were first described by the German
psychiatrist Alois Alzheimer in 1907 (reviewed in [16]) and since then many efforts have
been deployed in understanding the mechanism behind this pathology. Neurofibrillary
tangles are aggregates of the microtubule-associated protein tau that accumulate when
it is aberrantly processed and hyperphosphorylated [17]. The generation of amyloid
plaques, on the other hand, arise due to endoproteolysis of amyloid precursor protein
(APP), a type I membrane protein. As shown in figure 1.1 APP is subsequently cleaved by
the proteases β-secretase (also known as Bace1) and γ-secretase, to liberate β-amyloid
(Aβ) peptides. This process also generates a soluble APP ectodomain (sAPPβ), due to
β-secretase cleavage, and a membrane bound carboxy (C)-terminal fragment (C59), due
to γ-secretase cleavage [17].
1.2.1 Insulin signalling in Alzheimer’s disease
As described above, obesity or overweight in midlife is implicated as an independent risk
factor of AD in later life. The correlation between this neurodegenerative disease and
metabolic malfunctioning is also highlighted by the fact that AD patients show impaired
glucose metabolism, hyperinsulinaemia and insulin resistance [18] [19]. Moreover, brain
samples from AD patients display reduced insulin levels, insulin receptor density and
signalling [20]. The interconnection between the detrimental effects of AD and T2D
is so strong that several research groups refer to the neurodegenerative disease as
"type 3 diabetes" [21] [22], claiming that AD may represent a neuroendocrine disorder
that resembles, yet is distinct from diabetes mellitus. For the importance that insulin
implicates in key regulatory pathways of learning and memory in the central nervous
system (CNS), impaired insulin activity and signalling in the brain has been proposed to
promote and/or exacerbate AD neuropathology [23]. The intercorrelation between AD
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FIGURE 1.1. APP processing by β- and γ-secretases for the generation of Aβ. First,
the β-secretase Bace1 (β) cleaves APP to create the N-terminus of Aβ, generating the
membrane-bound C99 and the secreted sAPPβ ectodomain (blue). Second, C99 is cut by
the γ-secretase (γ) to generate the C-terminus of Aβ. The Aβ peptide (red) is then released
and secreted extracellularly. An intracellular domain, C59 (light blue), is also produced.
Original figure; based on [17].
and obesity was supported by an in vivo study in which Ho and colleagues used an AD
mouse model to study the effects of diet-induced obesity on the brain. The peripheral
insulin resistance that arose with excessive feeding was shown to reduce both the amount
and the signalling efficency of insulin in the brain of these mice, leading to an increase of
AD symptoms, like β-amyloid peptide generation and subsequent cognitive decline [24].
1.2.2 The β-secretase BACE1
Since the discovery of β-amyloid plaques in the brains of AD patients, a lot of effort has
been undertaken in discovering the protease responsible for their generation. It took
many years before different research groups identified this protease as the β-secretase
BACE1, a 501 amino acid type I transmembrane aspartic protease which is related to
the pepsin family and the retroviral aspartic proteases [25] [26] [27] [28] [29]. Despite
being majorly expressed in the brain, BACE1 protein is distributed broadly - in low
levels - among most peripheral tissues, with the exception of the pancreas which shows
robust expression [27]. BACE1 is not only present on the cell membrane, but is also
located within acidic intracellular compartments, including endosomes and trans-Golgi
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networks, for its optimal enzyme activity at acidic pH [17].
BACE1 role in the proteolytic cleavage of APP was first discovered using Bace1-depleted
neurones which showed abolished production of Aβ and deposition of β-amyloid plaques
[27] [30]. This central relevance for BACE1 in AD pathology is also highlighted by
increased BACE1 levels and activity in AD patient’s brains [31].
Although early reports on Bace1 whole-body knock-out mice showed no apparent adverse
effects, suggesting that inhibition of the β-secretase should not have any toxic effect due
to its physiological not-APP-related role [32], more recent studies have shown a wide
range of BACE1-related side effects, including hypomyelination, retinal pathology and
others (reviewed in [17]). A physiological role for BACE1 activity has for example been
shown in muscle where the secretase is involved muscle spindle maintenance, leading to
defects in coordinated movements in mice lacking one or both copies of Bace1 [33].
In light of the pathological correlation between AD and T2D, the question arose whether
BACE1 has a role in glucose metabolism as well. First evidence in this direction came
from a study by Meakin et al. which showed that whole-body knock-out of Bace1 displayed
improved insulin sensitivity and glucose homeostasis [34]. Additional studies have been
performed in vitro to further test the effects of BACE1 activity on glucose regulation
on a molecular level. In the skeletal muscle cell line C2C12, BACE1 inhibition was
shown to directly enhance glucose uptake and metabolism [35]. In line with this, over-
expression of Bace1 in the human neuroblastoma cell line SH-SY5Y reduced cellular
glucose metabolism and switched the cellular metabolic profile from oxidative to glycolytic
[36].
1.2.3 Therapeutic approaches against Alzheimer’s disease
Given the high incidence of AD and the immense therapy costs associated with it, much
research has been focusing on a potential cure that could stop or delay the onset of the
disease. In 2015 a report by the Alzheimer’s Association [37] stated that the market
introduction of a treatment in 2025 that could delay the onset of AD by five years could
reduce the prevalence of this neurodegenerative disease by approximately 42% in 2050.
To date, no reliable biomarkers of AD are known and there are no treatments able to
stop the cognitive decline in AD patients. Only moderate symptomatic benefits have
been reported by the use of drugs like cholinesterase inhibitors and the NMDA (N-
methyl-D-aspartate) receptor antagonist, memantine [38]. As the pathophysiology of AD
leads to Aβ overproduction and impaired Aβ clearance, recent approaches to counteract
the disease have been focusing on enhancing clearance of β-amyloid peptides from the
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brain [39] and blocking Aβ generation in the first place. As a promising example of this
approach, BACE1 inhibitors and γ-secretase inhibitors and modulators are thoroughly
being investigated [40].
1.2.4 The therapeutical potential of BACE1 inhibitors
Among all therapeutic approaches developed in the last decades, BACE1 inhibitors
have shown the highest potential in counteracting AD with many of such compounds
in phase II/III human clinical trials [17]. LY2811376 was one of the first drugs tested
in humans in the beginning of this millennium [41]. Despite rather modest potency on
BACE1 inhibition, this compound showed a robust Aβ lowering activity in both animals
and normal healthy volunteers (phase I trials). However, LY2811376 development was
terminated due to off-target toxicities in eye and brain. Since then other inhibitors with
high affinity binding to BACE1 and the ability to reduce Aβ production in vivo have been
discovered [42] [43] [44]. Of particular interest is Verubecestat (MK-8931), which was the
first BACE1 inhibitor to reach phase III clinical trials in patients with mild to moderate
AD [44]. The drug discovered by Kennedy and colleagues is orally administered and
shows reduced Aβ and sAPPβ in the cerebrospinal fluid of animal models and humans,
both healthy and with AD. Furthermore, Verubecestat did not show any of the side effects
previously attributed to BACE1 inhibition by other compounds. However more studies
are necessary in the context of BACE1-targeting therapeutics and a really effective cure
for AD is still far beyond.
1.3 Metabolic regulation of peripheral tissues
Obesity occurs when energy consumption in form of food intake chronically exceedsenergy expenditure. It has been known for many years that body weight is regulated
by the central nervous system, in particular the hypothalamic area of the brain [45] and
to-date many different nuclei within the hypothalamus have been characterised based on
their function in energy homeostasis regulation [46]. Although hormonal and neuronal
mechanisms in response to feeding behaviour are finely tuned by neuropeptides produced
by the brain, peripheral tissues also play a pivotal role, with pancreas, liver, adipose
tissue and skeletal muscle bidirectionally communicating with the brain to maintain the
proper body homeostasis [47].
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1.3.1 Adipose tissue
Adipose tissue (AT) is an important regulator of global energy homeostasis in the body
since it can store and provide energy in the form of lipids. AT is therefore a site of
continuous anabolic and catabolic processing of lipids. On the anabolic side lipids are
formed through lipogenesis, a process that converts excess carbohydrates into fatty
acids, which are then esterified and stored as triacylglycerols (TGs) [48]. Known key
players in lipogenesis regulation are fatty acid-binding proteins (FABPs), a family of
intracellular lipid chaperones, that regulate lipid trafficking and responses in cells [49].
The adipocyte-specific member of this family is FABP4 (also known as aP2), which is also
expressed in macrophages and plays an important role in the development of insulin
resistance in relation to metaflammation [49]. FABP4 is fundamental for AT homeostasis,
and mice with no or reduced expression of this protein showed increased body weight but
unaffected insulin sensitivity and glucose homeostasis [50] [51]. Catabolic processing
of lipids in AT on the other hand include the release of fatty acids into the circulation
under fasting conditions to provide fuel for energy-supplying β-oxidation both locally
and in peripheral tissues.
AT can be divided into three major subgroups (figure 1.2): white adipose tissue (WAT),
mainly located in the subcutaneous and intra-abdominal regions, brown adipose tissue
(BAT), primarily located in the interscapular region in rodents, and a thermogenically-
activated form of WAT named beige or brite (brown in white) adipose tissue [52].
All three adipose tissues arise from a mesodermal origin and pre-adipocytes of all
lineages share the expression of preadipocyte factor-1 (PREF1), a transmembrane protein
expressed on immature pre-adipocytes, which represses adipogenic differentiation [53].
Once cells undergo growth arrest, Pref1 expression gets down-regulated, triggering a
transcriptional cascade that leads to adipogenic differentiation. This process mainly
involves peroxisome proliferator-activated receptor γ (PPARγ) and CCAAT/enhancer-
binding proteins (C/EBPα, β and δ) [54]. The transcription factor PPARγ does not only
comprise the ability to promote the adipogenic expression cascade but also directly
regulates adipocyte metabolism, being able to induce lipogenesis and lipid storage, while
repressing lipolysis and the release of non-esterified fatty acids (NEFAs, discussed in 1.4)
from adipocytes in a diet-dependent manner [55]. Fully functional adipocytes later-on
express FABP4 [49].
Although adipocytes from all depots share a significant overlap in general adipogenic
metabolism, BAT and WAT are yet characterised by distinct differences that drive their
commitment and activation as will be further described below.
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FIGURE 1.2. The three classes of adipocytes. Adipose tissue is mainly composed of
adipocytes. These are divided into brown, white and beige adipocytes. Brown adipose tissue
(BAT), mainly located in the interscapular region, is characterised by adipocytes with multi-
locular lipid droplets. Thanks to the uncoupling protein 1 (UCP1)-containing mitochondria
and its high vascularisation and innervation, BAT is able to dissipate chemical energy as
heat. White adipose tissue (WAT), with various subcutaneous and intra-abdominal depots,
presents adipocytes with unilocular lipid droplets and is a major organ for the storage and
release of energy. Beige adipocytes are present within various WAT depots, in particular in
the subcutaneous ones. These cells have BAT-like characteristics and can be recruited by
cold exposure and other stimuli. Beige adipocytes show a much higher phenotypic plasticity
than BAT, being able to switch between a thermogenic or storage phenotype. From [52].
1.3.1.1 White adipose tissue
White adipose tissue is the most abundant type of AT and is mainly composed of white
adipocytes [5]. These cells are characterised by a unilocular lipid droplet which takes up
about 90% of the adipocyte mass and confers the cells their typical spheric shape (figure
1.2). In a steady state system the lipid release of white adipocytes equals lipid uptake
and lipogenesis. Yet, given the constantly changing nutritional availability during food
intake and fasting phases, white adipocytes exhibit a remarkable size plasticity, which
is unique for a non-neoplastic tissue [56]. As soon as lipid influx into white adipocytes
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exceeds lipid release, the cells are capable of increasing either in size (hypertrophy) or
number (hyperplasia) to furthermore constitute a safe storage site for fatty acids [56].
WAT is divided into different depots, the two main ones being subcutaneous adipose
tissue (SCAT) and intra-abdominal or visceral adipose tissue (VAT) [57]. The deposition
of lipids within the different depots occurs in a hierarchical manner: The primary site for
NEFA uptake is SCAT and only after the lipid storage capacity is saturated in this depot,
additional excess energy will be taken up by VAT [56]. For SCAT comprising the highest
capacity to protect from lipodystrophy, it is considered to be the safest fat depot and
accumulation of SCAT has minor detrimental effects on body homeostasis [58]. Increase
of VAT mass on the other hand plays a more dominant role in NEFAs release and is often
associated with obesity-related diseases, like T2D and cardiovascular complications [59].
Therefore, different WAT localisations implicate different roles in energy and glucose
homeostasis regulation.
Next to its role as storage site WAT has also been indicated as the main endocrine organ
in the body for it releases a vast range of hormones, known as adipokines [60]. Adipokines
can regulate various substantial processes, including appetite, energy expenditure, lipid
metabolism and insulin and glucose homeostasis [60]. The endocrine role of adipose
tissue with be described in more detail in chapter 1.4.
1.3.1.2 Brown adipose tissue
Brown adipose tissue, the key site for non-shivering thermogenesis, is mainly composed
of brown adipocytes, characterised by multilocular lipid droplets (figure 1.2). This tissue
was first discovered in hibernating animals and was known to be present in rodents
and newborn humans. However recent studies found presence of thermogenically active
BAT also in adult humans [61] [62] [63]. Rodents present a main BAT depot in the
interscapular region, whereas humans have BAT depots localised in the neck and the
supraclavicular and mediastinal regions [64]. Just like WAT, BAT is also an endocrine
organ and secretes several hormones (also known as batokines and lipokines) that regu-
late the cross-talk with the brain and other peripheral tissues [65]. Further details will
be given in the next chapter (1.4).
Non-shivering thermogenesis in BAT allows mammals exposed to cold to produce heat
apart from shivering [66]. Nutrients and oxygen available in the blood are combusted by
BAT and utilised to fuel heat production. This process relies on the activity of uncoupling
protein 1 (UCP1) in the inner mitochondrial membrane of brown adipocytes. UCP1 acts
as an electron transporter, uncoupling mitochondrial combustion of substrates from ATP
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production, instead producing heat and profoundly increasing energy expenditure (EE)
[60]. The high vascularisation of BAT allows the tissue to cope with the high demand for
nutrients and oxygen and also enables efficient distribution of heat throughout the body
[60].
BAT stimulation occurs through activation of the sympathetic nervous system via stim-
ulation of transient receptor potential (TRP) channels in sensory neurons [67]. The
sympathetic fibres innervating BAT release norepinephrine (NE) upon cold-exposure
to acutely activate thermogenesis [60]. NE binds to β-adrenergic receptors on the cell
surface of brown adipocytes, leading to lipolysis of locally stored lipids, which hence-
forth serve for β-oxidation, and at the same time up-regulation of UCP1 [68]. Among
the β-adrenergic receptors the β3-receptor subtype is the most effective activator for
BAT thermogenesis [60]. The cell intrinsic signalling upon β-adrenergic stimulation
is mediated by intracellular cyclic adenosine monophosphate (cAMP) release and pro-
tein kinase A (PKA) activation, which leads to the expression of thermogenic genes.
NE-induced genes includes among others Cebpb, ELOVL fatty acid elongase 3 (Elovl3),
which regulates endogenous synthesis of saturated very long chain fatty acids and TG
formation, and peroxisome proliferator-activated receptor gamma coactivator 1-alpha
(Ppargc1a), which is a key driver of mitochondrial biogenesis [60]. Other thermogenic
stimuli aside cold-exposure are β-adrenergic pharmaceuticals, hormones and ingestion
of caloric energy. Energy intake interestingly triggers diet-induced thermogenesis, i.e. an
even higher energy output by BAT than demanded for mere food metabolism [69].
BAT differs from WAT not only in its thermogenic capacity, but also in its develop-
ment, with brown adipocytes rising from precursors in the embryonic mesoderm, hereby
sharing lineage with skeletal muscle cells [70]. These multipotent precursors express
transcription factors such as paired box 3 (Pax3) [71], Pax7 [72], engrailed-1 (En1) [73]
and myogenic factor 5 (Myf5) [70], while white adipocytes mainly originate from Pax3-,
Pax7-, En1- and Myf5- precursors. Although it has been implied, that beige adipocytes
derive from the Myf5- lineage, it still remains unclear whether the process of browning
therefore represents a transdifferentiation phenomenon or whether beige adipocytes
develop from a separate precursor lineage [74]. Interestingly, a very low percentage
of white adipogenic progenitor cells were also found to be Myf5+ [5], underlining the
difficulty to identify markers exclusively limited to distinct adipogenic lineages. However
the concept of a shared progenitor lineage between brown adipocytes and skeletal muscle
cells is indisputable and clearly distinct from white adipogenic precursor pools.
Since the discovery of BAT in adult humans, estimations have been made, that 50%
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of the population possess the tissue in a thermogenically active form. Interestingly it
could also be shown that BAT activity significantly declines with both age and obesity
[75]. Human studies revealed that cold exposure leads to increased BAT activity and
decreased body fat mass, with an inverse correlation reported between the amount of
BAT and adiposity [76] [77]. This activation of brown fat occurred even in individuals
with chronically low basal BAT activity, highlighting the potential that this tissue has
in regulating whole-body homeostasis. It is therefore of greatest therapeutic interest to
enhance BAT activity in humans as treatment against obesity. Conventional weight loss
strategies and physical exercise often result in a hypometabolic state accompanied by
impaired release of appetite-suppressing adipokines due to rapid WAT loss. An activation
of BAT on the other hand could be able to circumvent the weight loss-induced appetite
enhancement and involuntary reduction in energy expenditure [69]. Unfortunately β-
adrenergic receptor agonists nowadays implicate low bioavailability [5] and various side
effects particularly on the cardiovascular system [78], leaving a potent BAT activator yet
to be discovered.
1.3.1.3 Beige adipose tissue
Some adipocytes within WAT have already been shown many years ago to be char-
acterised by a multilocular appearance and high levels of UCP1 when stimulated by
cold or β-adrenergic stimuli (figure 1.2) [79] [80]. Induction of these adipocytes strongly
correlates with the capacity to reduce obesity in mice [81]. This tissue was later named
beige or brite adipose tissue. Beige adipocytes share features of both white and brown
ones, having extremely low basal expression of UCP1 (as does WAT), but being able to
highly increase UCP1 levels and respiration rates when stimulated (as does BAT) [82].
Despite showing an expression footprint common to both WAT and BAT under specific
conditions, beige adipose tissue also has specific gene markers with the most promising
being TNF receptor superfamily member 9 (Tnfrsf9 or CD137), transmembrane protein
26 (Tmem26) and T-box 1 (Tbx1), which were identified in in vitro and in vivo studies
[83] [84]. However, an unequivocal gene set of beige markers is still debated.
In humans it has been shown that part of BAT depots could be composed of beige
adipocytes and stimulating the development of beige adipocytes within white fat (a
process known as browning) could reduce the detrimental effects of WAT accumulation,
leading to a healthier metabolic phenotype [83].
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1.3.2 Skeletal muscle
Skeletal muscle (SM) is one of the three main muscle types, together with cardiac and
smooth muscle, and is the major site for insulin-stimulated glucose utilisation, disposing
about 80% of total body glucose [85].
Defects in SM insulin homeostasis, with consequent insulin resistance, are a hallmark
of the metabolic dysfunctions leading to obesity. This tissue is able to increase glucose
transport upon insulin stimulation thanks to insulin-sensitive glucose transporters,
with the GLUT4 isoform being the best characterised [86]. It has been suggested that
insulin resistance in SM could occur due to defects in the recruitment of these glucose
transporters to the sarcolemma, the muscle cell membrane [86]. Physical activity can
influence muscle metabolism, with exercise training being shown to increase the number
of mitochondria in SM [87].
Necessary for the determination and terminal differentiation of SM, are the members of
the myogenic regulatory factors (MRF) family, a basic helix-loop-helix (bHLH) protein
family that consists of MYOD1 (myogenic differentiation 1, also known as MYF3), MYOG
(myogenin, also known as MYF4), MYF5 (myogenic factor 5) and MYF6 (also known as
MRF4 or Herculin) [88]. All four of them are able, when over-expressed, to convert non-
muscle cells to the myogenic lineage [88]. For example, ectopic expression of MYOD1 was
shown to activate muscle genes in a variety of differentiated cell lines, including dermal
fibroblasts, chondrocytes, smooth muscle, retinal pigmented epithelial cells, adipocytes,
and melanoma, neuroblastoma, osteosarcoma, and hepatoma cells [89]. These myogenic
factors are also involved in myogenesis during development and are expressed in a
temporally distinct manner: Myf5 is the first one to be detected in the somite, than Myog
and last MyoD, which continues to be expressed throughout development. Myf6 is instead
expressed transiently in the myotome and later re-expressed to become the predominant
MRF expressed in adult muscle [90]. Both MyoD and Myf5 have are not strictly required
for myogenic differentiation, with knock-out mouse models showing no apparent effects
on muscle development [91] [92]. Myog, on the other hand, is essential for proper skeletal
muscle formation and differentiation, with lack of the gene in mice leading to a severe
reduction of differentiated skeletal muscle and postnatal death [90]. These experiments
suggest that MyoD and Myf5 act to determine the myogenic lineage whereas Myog and
Myf6 are important for differentiation and maintenance of the terminally differentiated
state.
SM is a highly active tissue and require constant supply of ATP for the working muscles.
Creatine kinase (CK) plays a pivotal role in the homeostasis of cellular ATP by catalysing
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the conversion of creatine and consuming adenosine triphosphate (ATP) to create adeno-
sine diphosphate (ADP) and phosphocreatine (PCr), with the latter serving as an energy
reservoir for the rapid buffering and regeneration of ATP [93]. CK has five different
isoenzymes, of which CKM is the muscle specific one. In SM, CKM can form homodimers,
named CKMM, or heterodimers with the brain isoenzyme CKB, named CKMB [93].
CKM is considered a late myogenic marker and was shown to be accumulated in fully
differentiated myogenic cell cultures [94].
Another important expect of SM physiology is calcium regulation. In this context a
pivotal role is played by the troponin complex subunit Troponin T (TnT), which can
modulate calcium regulation of actin thin filament function and is essential for the
contraction of striated muscles [95]. In vertebrates TnT is encoded by three homologous
genes with specific spatial regulation: Tnnt1 is expressed in low skeletal muscle, Tnnt2
in cardiac muscle and Tnnt3 in fast skeletal muscle [95]. The two SM isoforms TNNT1
and TNNT3 are responsible for the binding to tropomyosin and anchoring to the thin
filament in the sarcomeres of slow or fast twitch skeletal muscle respectively, which
regulates the actin-activated myosin motor function [96].
Among the pathways critical for SM function there are also the ones involving mitochon-
drial oxidative metabolism and energy transduction. Indeed, decrease is mitochondria
has been shown since many decades to be a major effect of long-term muscle atrophy
[97]. In this context, the transcriptional coactivator PPARGC1α plays a fundamental
role and its expression in SM is sufficient to induce mitochondriogenesis [98].
As stated above SM shares a common lineage with BAT, with progenitor cells being able
to differentiate in both tissues. This was also supported by in vivo studies showing that
mice unable to differentiate skeletal muscle cells present increased brown fat, especially
in the dorsal cervical region [90]. This suggests that cells incapable of completing ter-
minal muscle differentiation give rise to brown adipocytes. Recent investigations found
specific molecular inter-players involved in this cell fate switch. Among these there is
PR domain containing 16 (Prdm16), whose ectopic expression in both immortalised and
primary myogenic cell lines led to a brown fat-like phenotype upon proadipogenic stimu-
lation [70]. However, it was already known since many years that the master regulators
of adipogenesis PPARγ and C/EBPα are able to drive myoblasts to transdifferentiate
into mature adipocytes, completely blocking cell myogenesis upon expression of the two
transcription factors [99].
In addition to the transdifferentiation between SM and AT, muscle stress (e.g. mus-
cle dystrophies, inflammatory myopathies, or caused by ageing, obesity, diabetes and
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other metabolic diseases) can lead to intramuscular fat deposition [100]. This includes
both acellular lipid droplets within the myofibers and interstitial adipocytes which are
PPARc2 positive [101]. Intra- and interfiber adipocytes are usually white, however also
brown adipocytes have been identified, which can support SM in heat production during
physical exercise [102].
As well as AT, SM has also been identified as an endocrine organ, which releases solu-
ble factors called myokines [100]. They are synthesised in the tissue especially during
contraction and exercise and can act in a paracrine or endocrine manner. Most of these
myokines are secreted by AT as well. These shared factors are called adipo-myokines
and include, among others, FGF21, IL-6 and myostatin [100].
1.4 Endocrine regulation of energy homeostasis
E nergy homeostasis is described by the first law of thermodynamics:
Energy intake – energy expenditure = energy stored
Energy intake consist of all the fuels ingested by an organism, while energy expenditure
(EE) is given by basal metabolic rate, thermogenesis and muscle action. As aforemen-
tioned excess fuels are stored as glycogen or TGs in different tissues, in particularly WAT,
which stores them as fat. This mechanism has a protective function as it prevents ectopic
lipid deposition in organs more metabolically active, like liver or SM [48]. The process of
maintaining energy homeostasis fulfilled by adipose tissue, referred to as homeostatic
regulation of adiposity and body weight, in regulated by the CNS through neuronal and
hormonal signals [47]. The release and regulation of peripheral hormones has a central
role in balancing whole-body homeostasis.
WAT, being a major endocrine organ, produces many hormones. One of the main WAT-
specific hormones is leptin that was first shown to regulate energy balance in mice [103]
and later in humans [104]. Leptin is released in the blood by white adipocytes in response
to their lipid content and can regulate food intake and EE via activating anorexigenic
neurons in the hypothalamus [105]. Suppression of appetite is stimulated by increasing
levels of leptin when fat mass increases. This stimulus is lost when WAT lipid content is
back to balance [105]. Another adipocyte-specific hormone is adiponectin that, similarly
to leptin, is able to repress energy intake while enhancing energy expenditure via the
hypothalamic regulation on the CNS [5]. Moreover this hormone can ameliorate fatty
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FIGURE 1.3. Endocrine regulation of brown adipose tissue. Brown adipose tissue (BAT)
releases endocrine factors that are able to target both the central nervous system (CNS)
and peripheral tissues (e.g. white adipose tissue, liver, pancreas, heart). Factors such as T3,
FGF21 and IL-6, can regulate organ cross-talk and therefore promote energy homeostasis
supplying substrates to fuel thermogenesis. These processes are achieved by BAT via
direct targeting of organs in the periphery or indirectly, via stimulating the CNS to trigger
systemic effects. The cross-talk between BAT and the CNS is bivalent, with external stimuli
(e.g. food intake, cold exposure) promoting the brain to elicit the release of endocrine factors
by BAT, generating a regulatory feedback loop. FGF21, fibroblast growth factor-21; IL-6,
interleukin-6; SNS, sympathetic nervous system; T3, triiodothyronine. Original figure;
based on [65].
acid oxidation and insulin sensitivity in SM and liver by stimulating AMPK activity
[57]. Surprisingly, although adiponectin improves global energy homeostasis in a similar
way as leptin, its expression is inversely correlated with fat mass [106]. Also primarily
released by WAT, is resistin whose expression follows adipocyte differentiation in vitro
[107]. This protein is positively regulated by C/EBPα and negatively by PPARγ. In mice it
was shown to increase upon HFD, positively correlating to FABP4, and to play a causative
role in the development of insulin resistance. In humans resistin was associated with the
development of obesity and insulin resistance, yet contradictory findings do not allow
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a definitive relationship between these pathology and the circulating adipokine [107].
Adipose tissue also produces non-esterified fatty acids (NEFAs). This adipocyte-derived
secreted products have long been known to be released in fasting condition to provide
nutrients to the rest of the body [57]. NEFAs circulating in the blood are able to regulate
glucose homeostasis via stimulating adipocytes and muscle to reduce glucose uptake and
hepatocytes to increase glucose output [57].
The other main hormone involved in whole-body energy regulation is insulin. Insulin is
secreted by pancreatic β-cells upon food intake in response to increased glucose levels in
the blood [108]. Insulin release promotes the uptake of glucose by peripheral tissues such
as liver, adipose tissue and muscle [108] while on the other hand repressing lipolysis [5].
Like leptin, insulin can regulate food intake through stimulation of specific neuronal
populations [109].
The thermogenic activity of brown fat, which has been shown to be able to counter-
act obesity, can be also regulated by a - BAT-specific - hormonal network [110]. This
complex regulatory network includes both hormones produced within brown adipocytes
and hormones released by other metabolically active organs such as brain, liver, heart,
skeletal muscle and WAT. A similar hormonal regulation could regulate as well browning
of beige adipose tissue (figure 1.3) [83]. However, brown fat hormonal footprint differs
from that of white fat, with the main WAT-released adipokines (e.g adiponectin and
leptin) being poorly expressed in this tissue, especially in highly active BAT [60]. This
supports the idea that hormones produced by brown and beige adipocytes are actively
released under conditions in which these two tissues are thermogenically activated [65].
Before being considered an endocrine organ, BAT was already known to release the
thyroid hormone triiodothyronine (T3) [111]. T3 is synthesised in brown adipocytes and
its production is increased under conditions of high BAT activity [111]. T3 is converted
from its inactive form thyroxine (T4) by the type 2 deiodinase DIO2, an intracellular
enzyme found also in BAT and SM, that regulates energy balance and may influence
glucose metabolism [112]. Other hormones have later been found to regulate glucose and
insulin homeostasis mainly via influencing hepatic and cardiac function. These include
insulin-like growth factor I (IGF-1), interleukin-6 (IL-6) and fibroblast growth factor-21
(FGF21) [65]. IGF-1 was propose to ameliorate diabetes complications via mimicking the
actions of insulin [113]. IL-6 is mainly known for its role as a pro-inflammatory agent,
but it was also shown to activate BAT by acting on the CNS in a sympathetic nervous
system (SNS)-dependent manner [114] and to ameliorate insulin secretion [115]. FGF21
is probably the major BAT hormone and was found to be released also by beige adipose
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tissue in both mice and humans [116] [117]. FGF21 endocrine activity regulates energy
homeostasis through signalling to many organs, including the CNS where it increases
metabolic rate [118]. In the periphery the hormone promotes cardioprotection and fatty
acid oxidation in heart [119] and it acts directly on the liver via inducing fatty acid
oxidation [120]. FGF21 was also demonstrated to protect from the detrimental effects of
diabetes [113].
Taken together, a complex network of hormones released by adipose tissue, especially
by brown adipocytes, is able to regulate energy and glucose homeostasis, headlining
the endocrine activity of BAT as potential target to counteract obesity and its related
diseases.
1.5 Metabolic regulation by microRNAs
In recent years many different strategies have been deployed in order to measureRNA species clinically relevant to various human diseases [121]. New technologies
allowed the discovery of many noncoding RNAs, whose regulatory potential is now being
exploited to target disease-related pathways (reviewed in [122]), including metabolic
ones involved in the development of obesity and its sequelae.
1.5.1 The noncoding genome
Only few decades ago that part of the genome not giving rise to proteins was consid-
ered ’junk DNA’. Surprisingly, although only 1-2% of the mammalian genome codes for
protein, advances in transcriptome sequencing demonstrated that more than 80% of it
is transcribed into RNA, leading to the production of many so-called noncoding RNAs
[123] [124] [125] [126] [127]. Noncoding RNAs were first discovered in lower organisms
thanks to early studies in plants (e.g. Arabidopsis [128]), invertebrates (e.g. Drosophila
[129]) and honey bee ([130]). Further sequencing analyses revealed the presence of many
classes of noncoding RNAs, with data from 2011 indicating an amount of 16592 noncod-
ing RNA genes, of which around 30% were long intragenic noncoding RNAs (a class of
long noncoding RNAs, lncRNAs), 10% microRNAs (miRNAs) and 9% small nucleolar
RNAs (snoRNAs) [131]. Some examples of noncoding RNA families are shown below.
Long noncoding RNAs are a heterogeneous class of regulatory transcripts characterised
by a length of more than 200 nt [125]. These noncoding RNAs share many characteristics
with protein-coding genes, differing in their inability to translate into protein. Moreover,
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in contrast to protein-coding transcripts, lncRNAs are expressed at lower levels, are less
evolutionarily conserved and less frequently associate with ribosomes [132]. Interest-
ingly, some lncRNAs do give rise to small peptides and can therefore act as both coding
and noncoding transcripts [133]. LncRNAs have multiple ways of action and different
roles in various processes, such as epigenetics regulation, cellular differentiation and
disease pathogenesis [134].
MicroRNAs are the best characterised class of noncoding RNAs. With a length of about
22 nt, they are estimated to target more than 75% of the gene transcripts through incom-
plete base-pairing to genes 3’ untranslated region (UTR) via a ∼7 nt region known as
miRNA seed [135]. Further details on miRNA biogenesis and function will be discussed
in the following chapters.
Small nucleolar RNAs have an intermediate size, spanning between 60 and 300 nt.
SnoRNAs are located in the nuclear compartment within which ribosomes are formed,
called nucleolus, where they help facilitating ribosomal RNA (rRNA) folding and stability
through sequence-specific 2’-O-methylation and pseudouridylation [136]. In recent years,
however, various non-canonical functions have also been described for specific snoRNAs,
including regulation of mRNA editing and alternative splicing and post-transcriptional
gene silencing by pathways which could involve miRNA-like mechanisms [137].
Another family of noncoding RNAs with size and function similarities to miRNAs, are
piwi-interacting RNAs (piRNAs). The biogenesis of piRNAs differs from miRNAs as such
is Dicer-independent and involves a subfamily of Argonaute proteins involved in main-
taining genome stability in germline cells [138]. These noncoding RNAs are transcribed
in genomic regions containing transcribed transposable elements and other repetitive
elements [122].
A newly discovered family of noncoding RNAs are circular RNAs (circRNAs). These are
characterised by a covalently closed circular RNA molecules, usually spanning exonic
sequences and spliced at canonical splice sites [139]. CircRNAs can be found in all
eukaryotic species and their expression varies in different cell types and can exceed the
abundance of linear mRNA or other noncoding transcripts [137]. These transcript are
enriched in the brain and their expression increases during foetal development [137].
Little is known about circRNA function and their tissue specificity, however in some
studies they have been found to regulate gene expression acting as miRNA sponges or
RNA-binding proteins [139].
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1.5.2 The biogenesis of microRNAs
MiRNAs were first discovered as regulatory
genes involved in various developmental pro-
cesses in C. elegans [140] [141]. Their process-
ing (Figure 1.4) starts in the nucleus where
they are transcribed by RNA polymerase II as
primary miRNAs (pri-miRNAs) 1000-3000 nt
long. These are then cropped into shorter 60-
70 nt long miRNA precursors (pre-miRNAs)
by a complex of the RNAse III endonuclease
Drosha and the microprocessor complex sub-
unit DGCR8 (also known as Pasha). The ∼2
nt long 3’ overhang of nuclear pre-miRNAs is
recognised by Exportin-5 enabling their nu-
clear export. In the cytoplasm they are then
cleaved into short miRNA duplexes by the
RNAse III endonuclease DICER1 (encoded by
the Dicer1 gene). In complex with TAR RNA-
binding protein 2 (TARBP2), DICER1 loads the
miRNA duplex onto Argonaute (AGO) proteins,
AGO1-8 in humans, to form the RNA-induced
silencing complex (RISC). One strand of the du-
plex remains as mature miRNA, whereas the
other strand is discarded from AGO. The RISC
complex allows miRNAs to actuate degradation
of messenger RNAs (mRNAs) or translational
repression via base-pairing to the 3’ UTR of
specific genes [142].
FIGURE 1.4. MicroRNA biogenesis. MicroRNAs (miRNAs) are transcribed as individual
primary miRNA (pri-miRNA) or together with host genes (mirtrons). After being processed
by the Drosha complex or the lariat-debranching enzyme, precursor miRNAs (pre-miRNAs)
are exported from the nucleus by exportin 5 (XPO5). Further processing by Dicer and TAR
RNA-binding protein 2 (TARBP2) generates mature miRNAs, which, after being loaded
into the RNA-induced silencing complex (RISC) can degrade protein-coding transcripts or
repress translation. Adapted from [122].
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An alternative pathway, discovered in Drosophila, generates miRNAs that derive from
short intronic hairpins named mirtrons (Figure 1.4) [143]. The biogenesis of these miR-
NAs differs from the canonical one so that it bypasses cleaving by Drosha and instead
involves mRNA splicing and intron lariat-debranching enzymes [144]. In contrast to
pri-miRNA hairpins, which generate functional RNAs from both 5’ and 3’ hairpin arms,
mirtron hairpins produce miRNAs only from their 3’ arms [143]. After this step, the
cleaved mirtrons reenter the canonical pathway and are transported to the cytoplasm by
Exportin-5 where they generate mature miRNAs - through DICER1 cleaving - which are
then loaded into the RISC complex [144].
MiRNAs have also been shown to derive from snoRNAs, transfer RNAs (tRNAs) or other
RNA species via Drosha/DGCR8-independent, Dicer-dependent pathways [145]. The only
claimed case, so far, for a Dicer-independent miRNA is miR-451, which derives from a
short pre-miR-451 generated by the Drosha/DGCR8 complex. This miRNA is directly
cleaved at the 3’-end by AGO2 and further trimmed by 3’-5’ exoribonuclease PARN to
produce the mature form of miR-451 [146] [147] [148].
However, all of these miRNAs, through the RISC-mediated inhibitory mechanism, can
regulate many biological processes and have been shown to play important roles in the
pathophysiology of many diseases [122].
1.5.3 DICER1 and its role in adipose tissue homeostasis
Given its pivotal role in the maturation of miRNAs, DICER1 as been extensively inves-
tigated in the past decades in many studies utilising straight or conditional knock-out
mouse models. These experiments revealed the enzyme to be required for normal devel-
opment, differentiation and physiology of most tissues, with the different phenotypes
being sometimes causally associated with removal of specific miRNAs [145]. Results from
miRNAs studies in AT showed that miRNAs may have important regulatory effects on
adipocyte differentiation and regulation. For this reason it was suggested that miRNAs
regulation by DICER1 could play a role in this context.
Early studies on the role of DICER1 in adipogenesis showed that the enzyme is required
for adipogenic differentiation of embryonic fibroblasts and primary pre-adipocytes in
mice [149]. Tamoxifen-induced Cre-driven ablation of Dicer1 in pre-adipocytes blocked
differentiation of these cells, reducing almost completely the expression of adipogenic
genes like Pparg, Fabp4 and the glucose transporter Glut4 [149].
Further studies by Mudhasani and colleagues investigated in an aP2-specific Dicer1
knock-out mouse line the role of this enzyme in the formation of white and brown adipose
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tissue [149]. Depletion of Dicer1 reduced the level of various adipogenesis-specific tran-
scripts and inhibited lipogenesis in white adipocytes, leading to decreased WAT mass.
Interestingly, lipogenesis in BAT was not affected, despite down-regulation of genes
involved in thermoregulation, including Ucp1, Cidea and Ppargc1a [149].
Moreover, adipose tissue has shown a global regulation of miRNAs associated with
physiological and pathological conditions in mice [150]. In particular, the expression
of many miRNAs decreased with ageing in SCAT, with more than 50% of the detected
miRNAs being down-regulated. This global down-regulation was associated with defects
in the expression of DICER1. Interestingly, this phenotype was completely prevented
by caloric restriction [150]. Mori and colleagues utilised a mouse model with an adipose
tissue-specific knock-out of Dicer1 (AdicerKO) to analyse the effects that reduced miRNA
processing could have on metabolism [151]. When fed a HFD, these mice exhibited
decreased WAT mass in parallel with increased BAT mass due to whitening, leading to
the development of lipodystrophy. This phenotype was associated with adipose tissue
inflammation, dyslipidemia and insulin resistance [151]. Furthermore, AdicerKO mice
showed age-associated detrimental effects, such as accelerated insulin resistance and
premature mortality [152]. The WAT-specific depletion of Dicer1 also affected other
organs, with increased mTORC1 activation in WAT and SM [152].
These studies highlight the central role that miRNAs and their DICER1-mediated
processing have in regulating multiple processes, including adipose tissue homeostasis.
1.5.4 MicroRNAs and adipose tissue metabolism
As mentioned above, miRNAs are able to regulate adipose tissue metabolism and have
been proposed to play a major role in the differentiation and function of both WAT and
BAT [153].
1.5.4.1 MicroRNAs in adipose tissue
For the immense regulatory network of miRNAs in tuning specific gene expression, there
has been a highly emerging field in the research of adipose tissue-specific miRNAs able
to regulate fat homeostasis (figure 1.5).
In this context, one of the first discovered miRNAs was miR-27, which was shown to neg-
atively regulate adipogenesis in both mice [155] [156] and humans [157]. Furthermore,
its expression was also proven to be reduced in BAT and SCAT upon cold stimulation
and additional gain- and loss-of-function experiments in vitro could confirm an inhibitory
effect of miR-27 on brown and beige adipogenesis [155] [157].
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FIGURE 1.5. MicroRNAs involved in adipose tissue and skeletal muscle differenti-
ation and function. Various miRNAs are able to positively or negatively regulate the
fate of fat and skeletal muscle progenitors, promoting adipocyte lineages or regulating the
switch between brown adipocytes and skeletal muscle cells. Original figure; based on [154].
Another negative regulator of adipose tissue metabolism is miR-149-3p. Upon fasting
this miRNA induces a subcutaneous-to-visceral fat switch, with SCAT acquiring many
of the morphological and molecular characteristics of VAT to preserve energy [158]. In
turn, knock-down of miR-149-3p in primary pre-adipocytes promotes differentiation in
beige adipocytes and in vivo leads to increased mitochondrial activity and EE. This effect
could be attributed to miR-149-3p targeting of Prdm16 [158].
Targeting another fat-specific transcription factor, Cebpb, miR-155 was able to suppress
the development of adipogenic and thermogenic programs both in vitro and in vivo [159].
Indeed, mice lacking miR-155 showed increased BAT function and browning of WAT
when exposed to cold. This was observed in both homozygous and heterozygous miR-155
knock-out mice. Over-expression of miR-155 on the other hand triggered the opposite
phenotype: mice displayed significantly reduced BAT size and weight along with an
impairment of its function, as shown by lower levels of thermogenic markers in this
tissue [159].
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While Cebpb is directly targeted and thus repressed by miR-155, it is also an indirect
target of miR-196a, resulting in opposing effects on the transcription factor. MiR-196a
activates CEBPβ expression and induces beige adipocyte differentiation through re-
pression of HoxC8, a negative regulator of CEBPβ [160]. This miRNA was shown to
be induced in WAT precursor cells after cold exposure or β-adrenergic stimulation and
over-expression of miR-196a in mice enhances EE and protects them from diet-induced
obesity [160].
Notably the regulation of adipogenesis is not only affected by single miRNAs, but also
entire miRNA families, such as miR-30. MiR-30c was shown to promote adipocytes
differentiation in humans [161] and, together with miR-30b, to enhance the thermogenic
capacity of brown and beige adipocytes [162]. Hu and colleagues could show that the
pro-adipogenic phenotype elicited by miR-30b/c is dependent on their targeting of the
3’-UTR of the receptor-interacting protein 140 (RIP140), a co-repressor of genes involved
in glucose uptake, glycolysis and oxidative phosphorylation in major metabolic tissues
such as fat, muscle, liver, and heart. Indeed, reinstatement of RIP140 suppressed the
up-regulation of BAT markers observed in brown adipocytes upon miRNAs knock-down
[162]. Moreover, miR-30b expression does not only affect, but it is also affected by cold-
and drug-induced BAT and SCAT stimulation in mice [163].
Interestingly several studies have not only identified a role for miRNAs in late differenti-
ation and thermogenic activity, but also in early developmental events of adipogenesis.
For example, miR-455 is a BAT-enriched miRNA that enhances adipocytes’ thermogenic
potential acting downstream of BMP7 and cold-induced pathways to promote brown
adipocyte lineage commitment [164]. Over-expression of this miRNA in vitro increases
the expression of key regulators of adipogenesis and BAT-markers not only in committed
brown and white adipocytes, but also in non-committed multipotent progenitor cells.
This phenotype was confirmed in vivo, with mice over-expressing miR-455 under the
control of the aP2-Cre (i.e. in FABP4 positive cells) showing an enhanced thermogenic
capacity upon stimulation of BAT [164].
One of the most recently discovered BAT-related miRNA is miR-32, which was also shown
to increase the thermogenic capacity of BAT [165]. Inhibition of the miRNA in mice led
to impaired thermogenic response upon cold induction and decreased EE. MiR-32 is
located in close proximity of a BAT specific super enhancer and it acts via the p38/MAPK
signalling pathway to increase FGF21 expression in BAT [165].
Interestingly, both WAT and BAT have been shown to generate a major fraction of
circulating exosomal miRNAs [151].
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1.5.4.2 MicroRNAs in brown adipose tissue/skeletal muscle cell fate
regulation
Due to the shared cell lineage of brown adipocytes and skeletal muscle cells and given
the ability by various transcription factors to drive transdifferentiation of myogenic and
white fat precursors to brown adipocytes, lot of interest rose in last years on the role
played by miRNAs in regulating this fate switch. Two main miRNAs, namely miR-133
and the miR-193b-365 cluster, came to attention in this context.
MiR-133, comprising the two closely related miR-133a and miR-133b, is a muscle-specific
miRNA (myomiR) which was found to be expressed also in BAT and, to a lower degree, in
SCAT [166]. Loss- and gain-of-function experiments in brown pre-adipocytes could prove
the miRNA to induce and inhibit brown adipogenesis respectively, herein affecting cell
differentiation, but not proliferation. Interestingly, knock-down experiments in primary
cells revealed that the pro-adipogenic effect of miR-133 inhibition was limited to SCAT
but not VAT, which is known to be less prone to browning induction in rodents. The
negative regulation of BAT by miR-133 was demonstrated to occur due to the suppression
of Prdm16 expression, as confirmed via luciferase assays [166]. In line with the in vitro
results, knock-out of miR-133a in mice led to increased brown and thermogenic gene
programs in SCAT [167]. Furthermore, these mice exhibited enhanced insulin sensitivity
and glucose tolerance associated with increased thermogenic capacity upon cold exposure
[167].
MiR-193b and miR-365, which are encoded within the same miRNA cluster in the
genome, were first identified as BAT-enriched after genome-wide miRNA analysis of BAT,
SCAT and SM [168]. Expression of these miRNAs was up-regulated during adipogen-
esis and down-regulated in BAT of genetically obese ob/ob mice. In vitro experiments
in primary brown adipocytes revealed decreased brown adipogenesis accompanied by
increased expression of myogenic markers upon inhibition of the cluster [168]. The same
results were obtained in the myogenic cell line C2C12. MiR-193b-365 was suggested to
act via targeting the adipogenesis inhibitor RUNX1 translocation partner 1 (Runx1t1)
and the pro-myogenic genes cell adhesion associated, oncogene regulated (Cdon) and
insulin like growth factor binding protein 5 (Igfbp5) [168]. However, further in vivo
studies on mice lacking the miR-193b-365 cluster failed to validate the in vitro findings
observed in BAT [169]. These mice showed no difference in BAT regulatory networks and
in their thermogenic response to cold or β3 adrenergic stimulation compared to control
littermates. It has been hypothesised that this discrepancy between in vitro and in
vivo indications could rely in a compensatory down-regulation of miR-133, whose levels
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were reduced in the BAT of the in vivo mouse model [169]. In fact, miR-133 deficiency
could completely mitigate the effects of miR-193b depletion, leading to an opposite BAT
response [166] [167].
All of these studies highlight the multi-faceted role that miRNAs have in regulating
adipose tissue differentiation and activity on various levels, making them potential
therapeutical targets against obesity-related metabolic impairment.
1.6 Objectives
Obesity is a major burden of our society, with increased adiposity and impaired glucose
homeostasis increasing the risk for related diseases such as T2D and neurodegenerative
pathologies (1.1). Brown adipose tissue activation has been proposed as a therapeutic
target to counteract obesity and its sequelae (1.3.1.2). MicroRNAs have been shown to
play an important role in maintaining brown adipose tissue homeostasis, both globally
[170] and concerning specific miRNA effects (1.5.4).
In light of this, the aim of this study was to discover and characterise novel miRNAs
that could potentially regulate energy homeostasis via enhancing brown adipose tissue
metabolism. For this purpose, expression of miRNAs was analysed in models of altered
BAT homeostasis and putative targets were tested for in vitro functionality, both in
brown adipogenesis and myogenesis, two processes that share a common progenitor
origin.
MicroRNA-mediated regulation of BAT can trigger metabolic pathways involved in
whole-body homeostasis. In order to unravel downstream regulators of candidate miR-
NAs involved in these pathways in vitro and in vivo techniques were used to first discover
these molecules and then characterise their impact on brown adipose tissue and whole-
body homeostasis.
25
C
H
A
P
T
E
R
2
MATERIALS AND METHODS
2.1 Animal care
All experimental animals were maintained on a C57BL/6 background and housed in
a pathogen-free facility. A 12 h light/dark cycle and a temperature of 22-24 °C was
maintained. Care of animals was within institutional animal-care committee guide-
lines. All procedures were approved by local authorities (Bezirksregierung Köln) and
regional authorities (Tierschutzkommission acc. §15 TSchG of the Landesamt für Natur,
Umwelt und Verbraucherschutz North Rhine Westphalia, internal reference number
84-02.04.2014.A184 and 84-02.04,2014.A068) and fulfilled National Institutes of Health
guidelines. Unless otherwise indicated, animals were allowed ad libitum access to food
and drinking water.
2.2 Experimental diets
All mice were fed ad libitum normal chow diet (NCD, Teklad Global Rodent no. 5.2018.R12;
Harlan). For diet-induced obesity experiments, mice were fed a high-fat diet (HFD, diet
identification no. D12492; Research Diets) containing 26.2% carbohydrates, 26.3% pro-
tein and 34.9% fat (60% calories from fat) from four weeks of age.
BACE1 inhibitor (RO5508887, Figure 2.1) was supplied by Roche and previously tested
for mice experiments [43]. For RO5508887 treatment, C57BL/6 mice were fed HFD for
three weeks after weaning and afterwards, cages were randomized and half of the cohort
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received HFD supplemented with RO5508887 for an additional 12 weeks. To achieve a
RO5508887 dose of 10 mg kg-1 body weight per day an average food intake of 3 g per
mouse per day of HFD ± RO5508887 was considered.
FIGURE 2.1. Chemical structure of BACE1 inhibitor RO5508887.
2.3 Experimental mouse models
Specific brown adipose tissue reduction of Dicer1 expression was achieved using Cre
recombinase-mediated excision of LoxP-flanked (“floxed”) gene sequences. Therefore,
mice homozygous for floxed alleles of Dicer1 (Dicer1LoxP/LoxP) were interbred with mice
expressing Cre recombinase under control of the BAT-specific uncoupling protein 1
(Ucp1) promoter (Ucp1-Cre+/- mice). Ucp1-Cre mice were generated as described in [171].
Resulting Dicer1LoxP/+ ; Ucp1-Cre+/- knock-out mice (Dicer1∆BAT/+) were compared with
Dicer1LoxP/+; Ucp1-Cre-/- littermates (controls).
Tissues from mice (C57BL/6) exposed to 4 °C for 1 or 7 days were obtained from the
laboratory headed by Jörg Heeren (University Medical Center Hamburg - Eppendorf,
Germany).
All other experiments were performed using C57BL/6 mice.
2.4 Genotyping
2.4.1 DNA isolation
Mouse tail biopsies were taken at weaning age and digested overnight at 56 °C and 450
rpm in 300 µl tail lysis buffer. The buffer was composed of 50 mM KCl, 1.5 mM MgCl2,
10 mM Tris-HCl pH 8.3, 0.45% Tween20, 0.45% Nonidet P-40 and freshly added 100
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µg/ml Proteinase K in H2O. Proteinase K was then inactivated by shaking at 94 °C and
450 rpm for 15 min.
2.4.2 Polymerase chain reaction (PCR)
For genotyping, 5 µl of previously extracted genomic DNA (2.4.1) were added to 20 µl
of corresponding PCR master mix and polymerase chain reaction (PCR) was performed
using the primers listed in Table 2.1. PCR master mix contained approximately 25 pMol
of each primer, 25 µM dNTP mix, 1% Dream Taq Green Buffer (Thermo Fisher Scientific)
and 1 unit Dream Taq DNA polymerase (Thermo Fisher Scientific) per 25 µl reaction.
PCRs were performed using the following programs:
Ucp1-Cre
Temperature [°C] Time [m:s]
95.0 5:00
95.0
61.0
72.0
0:30
0:45
1:00
39 x
72.0 10:00
4.0 ∞
Dicer1-flox
Temperature [°C] Time [m:s]
95.0 3:00
60.0 1:00
72.0 2:00
95.0
60.0
72.0
0:30
0:40
0:30
34 x
72.0 3:00
4.0 ∞
2.4.3 Agarose gel electrophoresis
PCR products from genotyping were visualised in 2% agarose gels containing 5% Midori
Green Advance DNA stain (Nippon Genetics Europe). DNA fragments were separated at
120 V and visualised under UV light. Expected products size are indicated below:
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Expected products for Ucp1-Cre:
WT: 554 bp
WT / Tg: 554 bp and 336 bp
Expected products for Dicer1-flox:
WT: 254 bp
WT / flox: 254 bp and 384 bp
fox / flox: 384 bp
Table 2.1: List of primers for genotyping PCR.
PCR Name Sequence (5’-3’)
Ucp1-Cre
Ucp1-Cre_F
Ucp1-Cre_R1
Ucp1-Cre_R2
CAAGGGGCTATATAGATCTCCC
ATCAGAGGTGGCATCCACAGGG
GTTCTTCAGCCAATCCAAGGG
Dicer1-flox
Dicer1-flox_F
Dicer1-flox_R
Dicer1-flox_Fwt
GGTTACATGGCTAGACTCAAAGC
AGGTGCCTTTCGTTTAGGAAC
AAAGCAGAACTCTAATGCCCC
2.5 Mice phenotyping
2.5.1 Body weight
Body weight of HFD ± RO5508887-fed mice was assessed weekly for each individual
mouse for ages 4-19 weeks.
2.5.2 Food intake
Food intake of HFD ± RO5508887-fed mice was quantified using standardised racks
with defined amounts of diet provided. The food pellets were exchanged every three
days throughout the experiment (12 weeks), residual pellets weighed and food intake
calculated per mouse and day.
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2.5.3 Glucose tolerance test (GTT)
For glucose tolerance test, mice were fasted for 16 h overnight. Fasted blood glucose
levels were measured using a glucometer (Contour, Bayer Diabetes Care). Following
intraperitoneal administration of insulin 0.75 U per kg of body weight (Actrapid; Novo
Nordisk), blood glucose levels were recorded after 15, 30 and 60 min.
2.5.4 Insulin tolerance test (ITT)
For insulin tolerance test, baseline blood glucose levels were measured using a glucometer.
Following intraperitoneal administration of 2 g glucose per kg of body weight (20%
glucose, Delta select), blood glucose levels were recorded after 15, 30, 60 and 120 min.
For determination of insulin tolerance, 15, 30 and 60 min values were calculated relative
to baseline blood glucose levels for each individual mouse.
2.5.5 Insulin and leptin serum analysis
Serum levels of insulin and leptin were measured by enzyme-linked immunosorbent
assay (ELISA) according to manufacturer’s instructions (mouse-rat insulin ELISA, mouse
leptin ELISA, Crystal Chem) in fasted animals at 8-9 weeks of age.
2.5.6 Metabolic cages
Metabolic measurements were obtained using a PhenoMaster System (TSE systems).
Animals were allowed to adapt to the single housing in metabolic cages (7.1 liter) for a
training phase of five days. Food and water were provided ad libitum in the appropriate
devices and measured by the built-in automated instruments. Parameters of indirect
calorimetry were measured for 72 h.
2.5.7 Body mass composition
Lean and fat mass of HFD ± RO5508887-fed mice were determined using nuclear
magnetic resonance (NMR Analyzer minispeq mq7.5, Bruker Optik) in live mice at 19
weeks of age.
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2.6 Thin-layer chromatography-mediated
quantification of lipids
Thin-layer chromatography (TLC) was performed at the CECAD lipidomic facility
(Cologne, Germany) headed by Dr. Susanne Brodesser. Frozen skeletal muscle and
liver samples were homogenized in H2O (100 mg of tissue per 1 ml) using the Precellys
24 Homogenisator (Peqlab) at 6,500 rpm for 30 s. The protein content of the homogenate
was routinely determined using bicinchoninic acid and lipids were extracted as described
in [172]. The lipid extract was applied to 20×10 cm high-performance thin-layer chro-
matography (HPTLC) Silica Gel 60 plates (Merck), which were pre-washed twice with
chloroform/methanol 1:1 (v/v) and air-dried for 30 min. For quantification of triacylglyce-
rols, each lane of the TLC plate was loaded with the equivalent of 5 µg (liver) or 9 µg
(skeletal muscle) of protein. The TLC solvent system used for detection of triacylglycerols
was hexane/toluene 1:1 (v/v), followed by hexane/diethyl ether/glacial acetic acid 80:20:1
(v/v/v). For quantification of cholesterol and free fatty acids, the equivalent of 150 µg
(liver) and 700 µg (skeletal muscle) of protein was applied to 20×20 cm TLC plates,
which were developed in hexane/diethyl ether/formic acid 30:50:1 (v/v/v). Quantitative
analytical TLC determination was performed as described in [172].
2.7 Cell culture
2.7.1 Mycoplasma test
Prior to usage cells were tested for mycoplasma contamination using the PCR My-
coplasma Test Kit (AppliChem) according to manufacturer’s protocol.
2.7.2 Growth medium
All cell lines were maintained in growth medium composed of Dulbecco’s modified Eagle’s
medium (DMEM, Thermo Fisher Scientific) containing 4.5 g l-1 glucose supplemented
with 10% fetal bovine serum (FCS, Biochrom AG), 1% L- glutamine (Thermo Fisher
Scientific), 1% penicillin/streptomycin (P/S, Thermo Fisher Scientific), 1% minimum
essential medium non-essential amino acids (MEM NEAA, Thermo Fisher Scientific,)
and 1% sodium pyruvate (Thermo Fisher Scientific).
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2.7.3 HEK293
HEK293 cells were obtained from Leibniz-Institut DSMZ (Deutsche Sammlung von
Mikroorganismen und Zellkulturen).
2.7.3.1 Transfection of HEK293
For transfection, 1×105 cells were seeded per well in 24-well plates and grown to con-
fluence in growth medium. One hour before transfection, the medium was changed to
growth medium without antibiotics. 400 ng DNA of reporter construct together with 100
nM miRIDIAN microRNA mimic (Thermo Scientific, Dharmacon) were transfected using
Lipofectamine® 2000 Reagent (1 mg/ml, Thermo Fisher Scientific, 52758) according to
the manufacturer’s protocols. Sequences of the utilised miRIDIAN microRNA mimics
are indicated in Table 2.2.
Table 2.2: List of sequences for in vitro loss- or gain-of function experiments.
Experiment Name Sequence (5’-3’) Concen-
tration
miRCURY
LNA™ Power
Inhibitor
Negative Control A
mmu-miR-193b
hsa-miR-328
GTGTAACACGTCTATACGCCCA
CGGGACTTTGTGGGCCAGT
GGAAGGGCAGAGAGGGCCA
100 nM
100 nM
100 nM
miRIDIAN
microRNA
mimic
Negative Control #1
mmu-miR-193b-3p
mmu-miR-328-3p
Catalog Item (CN-001000-01-05)
AACUGGCCCACAAAGUCCCGCU
CUGGCCCUCUCUGCCCUUCCGU
100 nM
100 nM
100 nM
Antisense
LNA™
GapmeR
Scrambled GapmeR
mmu-Bace1_1
mmu-Gprc5b_1
GACGGTAACTAGGCGA
ATTCGCATCGCATAG
AGTGTCGAAGTAGTT
80 nM
80 nM
80 nM
2.7.4 Immortalised brown pre-adipocytes (PIBA)
PIBA cells were generated in-house using standard protocols. [173]
2.7.4.1 Transfection of PIBA
For transfection, 5×104 cells were seeded per well in 6-well plates and grown to con-
fluence in adipogenic differentiation medium (2.7.4.2). One hour before transfection,
the medium was changed to differentiation medium without antibiotics. For transfec-
tion, miRCURY LNA™ Power Inhibitors (Exiqon), miRIDIAN microRNA mimic (Thermo
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Fisher Scientific, Dharmacon) or Antisense LNA™ GapmeRs (Exiqon) were diluted to the
desired concentration and transfected using Lipofectamine® 2000 according to the manu-
facturer’s protocols. Sequences and concentrations of utilised miRCURY LNA™ Power
Inhibitors, miRIDIAN microRNA mimics or Antisense LNA™ GapmeRs are indicated in
Table 2.2.
2.7.4.2 Induction and differentiation
For adipogenic differentiation, cells were seeded in growth medium supplemented with
20 nM human insulin solution (Sigma-Aldrich, I9278-5ML) and 1 nM 3,3’,5-Triiodo-L-
thyronine (T3, Sigma Aldrich, T2877) (differentiation medium). Once 100% confluent,
the medium was switched to differentiation medium supplemented with 125 nM in-
domethacin (Sigma-Aldrich, I7378), 0.5 mM isobutylmethylxanthine (IBMX, Sigma
Aldrich, I5879-5G) and 0.5 µM dexamethasone (Sigma-Aldrich, D1756) for 24 h. The
medium was then switched to differentiation medium for the next two days before
samples collection.
2.7.5 3T3-L1
3T3-L1 cells were acquired from American Type Culture Collection (ATCC).
2.7.5.1 Transfection of 3T3-L1
For transfection, 5×104 cells were seeded per well in 6-well plates and grown to confluence
in growth medium. One hour before transfection, the medium was changed to growth
medium without antibiotics. Lipofection was carried out as described for PIBA cells
(2.7.4.1) using a concentration of 50 nM. Sequences of utilised miRCURY LNA™ Power
Inhibitors, miRIDIAN microRNA mimics or Antisense LNA™ GapmeRs are indicated in
Table 2.2.
2.7.5.2 Induction and differentiation
For adipogenic differentiation, cells were seeded in growth medium and when 100%
confluent the medium was switched to growth medium supplemented with 20 nM human
insulin solution, 0.5 mM IBMX and 0.5 µM dexamethasone for 24 h. The medium was
then switched to growth medium supplemented with 20 nM human insulin solution for
the next four days before samples collection. The medium was changed every two days.
33
CHAPTER 2. MATERIALS AND METHODS
2.7.6 C2C12
C2C12 myoblast cells were acquired from American Type Culture Collection (ATCC).
C2C12∆Bace1 cells were generated as described in 2.8.
2.7.6.1 Transfection of C2C12
For transfection, 1×105 cells were seeded per well in 6-well plates and grown to con-
fluence in growth medium. One hour before transfection, the medium was changed to
myogenic differentiation medium (2.7.5.2) without antibiotics. Lipofection was carried
out as described for PIBA cells (2.7.4.1). Sequences of utilised miRCURY LNA™ Power
Inhibitors, miRIDIAN microRNA mimics or Antisense LNA™ GapmeRs are indicated in
Table 2.2.
2.7.6.2 Myogenic differentiation
For myogenic differentiation, growth medium was switched to DMEM supplemented
with 1.5% Hi Horse Serum (Thermo Fisher Scientific, 26050-088), 1% L- glutamine and
1% P/S (myogenic differentiation medium) at 100% confluence. Medium was changed
every two days for the subsequent five days before sample collection.
2.7.6.3 Adipogenic differentiation
For forced adipogenic differentiation of C2C12, when cells were 100% confluent growth
medium was switched to growth medium supplemented with 850 nM human insulin
solution, 1 µM rosiglitazone (Sigma-Aldrich, R2408-10MG), 1 nM T3, 0.5 µM dexametha-
sone, 0.25 mM IBMX and 125 nM indomethacin (adipogenic induction medium) for 48 h.
The medium was then switched to growth medium supplemented with 160 nM human
insulin solution and 1 µM rosiglitazone (adipogenic differentiation medium) for three
days before sample collection.
2.7.6.4 Conditioned media adipogenic differentiation
C2C12 and C2C12∆Bace1 seeder cells were plated in a 15 cm dish and once 100% confluent,
medium was replaced with 13 mL of growth medium. After 24 h the medium was collected
(conditioned medium) and replaced with 13 mL of fresh growth medium. The conditioned
medium was collected daily. 1×104 wild-type C2C12 were seeded in 6-well plates in
conditioned medium from both cell lines supplemented with 10% FCS, 1% L- glutamine
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1% P/S, 1% MEM NEAA and 1% sodium pyruvate (conditioned growth medium). After
three days of conditioned growth medium, when C2C12 cells were 100% confluent the
medium was switched to conditioned growth medium supplemented as the adipogenic
induction medium in 2.7.6.3. The medium was changed daily for 2 days. Subsequently
the medium was switched to adipogenic differentiation medium (2.7.6.3) for three days.
C2C12 cells were then collected for RNA or protein isolation.
2.8 CRISPR/Cas9 generation of C2C12∆Bace1
For generation of a stable Bace1 knock-out in C2C12 cells using CRISPR/Cas9 technol-
ogy, a modified pX330 vector [174] [175] containing two gRNAs and carrying a GFP-
puromycin selection cassette was used. The plasmid was provided by Dr. Stefan Frank
and generated at the Max-Planck Institute for Molecular Biomedicine (Münster, Ger-
many).
The knock-out strategy was based on [32]. In brief, deletion of exon 2 (89 bp) from Bace1
genomic DNA results in loss of function of Bace1 translation by generating a frameshift
(premature STOP codon in exon 3).
2.8.1 GuideRNA generation
A template DNA sequence for the gRNA was prepared as annealed oligonucleotides and
inserted into the BbsI-digested vector using the primers listed below. The second gRNA
was inserted using a SapI-mediated Golden Gate assembly method for the concatemeriza-
tion of gRNA cassettes using the primers listed below. gRNAs sequences were generated
using the CRISPR Design online tool (http://crispr.mit.edu/). Quality score represent the
faithfullness of on-target activity computed as 100% minus a weighted sum of off-target
hit-scores in the target genome. No high-scoring off-targets fell in marked gene regions.
GuideRNAs BbsI (Quality score 86)
Forward: 5’- CACCGCTGCTCTTATTCCGTGGAC - 3’
Reverse: 5’- AAACGTCCACGGAATAAGAGCAGC - 3’
GuideRNAs SapI (Quality score 78)
Forward: 5’ - ACCGAGCCTTTCTTCTACTAGGG - 3’
Reverse: 5’ - AACCCCTAGTAGAAGAAAGGCTC - 3’
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2.8.2 Vector generation
For CRISPR/Cas9 vector generation, restriction digestion of 1 µg of vector with FastDi-
gest BbsI (Thermo Fisher Scientific) was performed for 30 min at 37 °C. The obtained
vector was purified using the MinElute PCR Purification kit (Qiagen) following manufac-
turer’s instructions.
1 µl of 100 µM solution of forward and reverse primers (2.8.1) was phosphorylated by T4
polynucleotide kinase (New England Biolabs) for 30 min at 37 °C. Annealing took place
at 95 °C for 5 min and subsequent cooling to 25 °C at a cooling rate of 5 °C/min.
Ligation of 1 µl of oligo reaction (1:200 dilution in H2O) with 50 ng of digested vector
was assessed using the QuickLigase kit (New England Biolabs) for 20 min at room
temperature according to manufacture’s instructions.
Degradation of unspecific recombination products was performed with the PlasmidSafe
DNase kit (EpiCentre) for 30 min at 37 °C following manufacturer’s protocol.
2.8.3 Cell transformation and clone selection
2.5 µl of the obtained vector (2.8.2) were transformed into XL10-Gold Ultracompetent
Cells (Agilent) and plated overnight on LB-ampicillin plates. Bacterial colonies were
resuspended in 30 µl H2O and lysed at 95 °C for 5 min. 3 µl of the lysate were used
to identify positive clones by colony PCR (annealing at 64 °C) using the respective
forward primer (2.8.1) and as reverse primer 5’ - GGAAAGTCCCTATTGGCGTT - 3’.
PCR products were run on a 2% agarose gel for 20 min at 120 V and positive clones were
further verified by sequencing (2.10).
After correct insertion of the first gRNA, the procedure was repeated on the BbsI-digested
plasmid, this time using FastDigest SapI (Thermo Fisher Scientific).
2.8.4 Cell transfection and selection
C2C12 cells were transfected with 3 µg of CRISPR/Cas9 plasmid using FuGENE® Trans-
fection Reagent (Promega) according to the manufacturer’s protocol.
After 24 h of transfection efficiency was visually verified via GFP expression and
puromycin selection (5 µg/ml, Thermo Fisher Scientific) was performed for 72 h. Puromycin-
resistant cells were trypsinised and plated as single cells on a 96-well plate. For PCR
screening of positive cells, DNA was isolated using the QuickExtract™DNA Extraction
Solution (Epicentre) and samples were incubated at 68 °C for 15 min followed by 95 °C
for 8 min. PCR was performed using the primers listed in Table 2.3 following the strategy
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shown in Figure 4.7 c. The PCR program used was as follows:
Temperature [°C] Time [m:s]
95.0 3:00
95.0
59.0
72.0
0:30
0:30
1:00
34 x
72.0 3:00
4.0 ∞
Further validation was performed via DNA sequencing (2.10).
Table 2.3: List of primer sequences for clone selection.
Name Method of validation Sequence (5’-3’)
Bace1_ex2_in_F PCR IN GGTCCAGAGCCGTCTGTCT
Bace1_ex2_in_R PCR IN ACCCCTCCCCAGGACTTAC
Bace1_ex2_out_F PCR OUT TTTCTGACGATGGCACACAT
Bace1_ex2_out_R PCR OUT CACCCTTTCCCACACTGTCT
2.9 Oxygen consumption rate (OCR) analysis
For OCR quantification, 5,000 or 10,000 PIBA and C2C12 cells respectively were seeded
into Seahorse XFe96 (Seahorse Bioscience, Agilent) cell culture plates and transfected/
differentiated as described in 2.7. One hour prior to the assay both PIBA and C2C12
cells were given XF Base medium (Seahorse Bioscience, Agilent) supplemented with 1
mM sodium pyruvate, 2 mM L-glutamine, and 10 mM glucose (pH 7.4).
The assay was set as follows: 3 measurements (3 min mixing plus 3 min measuring each)
for basal respiration, 3 measurements after oligomycin (1 µM) injection, 3 measurements
after FCCP (1 µM) injection and 3 measurements after rotenone/antimycin A (0.5 µM)
injection. Oligomycin treatment allowed quantification of ATP production via inhibiting
ATP synthase (complex V), FCCP (Carbonyl cyanide-4 (trifluoromethoxy) phenylhydra-
zone) uncoupler caused maximal cellular respiration and rotenone/antimycin A treatment
revealed the amount of non-mitochondrial respiration via inhibiting complex I/III of the
mitochondrial electron transport chain.
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2.10 Extraction and sequencing of DNA fragments
For purification of DNA fragments from an agarose gel the QIAEXII Gel Extraction Kit
(Qiagen) was used following manufacturer’s instruction and eluted in 20 µl H2O. 3 µl of
purified DNA fragments were ligated into pGEM®-T Easy Vector (Promega) according to
manufacturer’s protocol for 4 h at room temperature.
2 µl of ligated vector were transformed into XL10-Gold Ultracompetent Cells (Agilent)
and plated overnight on LB-ampicillin plates. Subsequent positive colonies were ex-
panded overnight in 5 ml LB-ampicillin medium and DNA isolated using the Plasmid
Miniprep Kit I, peqGOLD (Peqlab). 30 µl of 50 ng/µl isolated DNA were sent to GATC
Biotech for DNA Sanger sequencing.
2.11 Dual luciferase reporter assays
For the generation of reporter constructs, fragments containing either the wild-type
or mutated miR-193b/miR-328-binding sites of the 3’-UTR of potential miRNA target
genes were cloned behind the STOP codon of the firefly luciferase open reading frame
Table 2.4: List of 3’-UTR primer sequences.
3’-UTR Forward sequence (5’-3’) Reverse sequence (5’-3’)
Bace1
GCTAGCGGCTAATAAGCCCTTTTT
CCCC
GCTAGCGGCTAATAAGCCCTTTTT
CCCC
Gprc5b
GAGCTCAAAGAAAGCTAGGGCTGT
GTGGG
GCTAGCCTCTCATCAGCTCACATG
GTCGC
Gprc5c
GAGCTCGGAAGCAGGTTGATTTAG
AGAGGG
GCTAGCTCCTCACAGAGGAGCAG
GATCC
Gpsm1
GAGCTCAGTCTTTTCCCTCAAGCC
CTGCC
GCTAGCTACCTCTCGGGTCAGAA
AGGACCC
Lmod1
GAGCTCAAGCACGTCACAGAGAAG
ATGGC
GCTAGCAAAACAGGGCCTCTGTG
CTGGG
Myod1
GAGCTCGAGATCGACTGCAGCAG
CAGAGG
GCTAGCTATTTCCAACACCTGAGC
GAGCG
Pax7
GAGCTCGGAAACCTGGTTCCCTG
AAAGGG
GCTAGCCAAAAGGAGAACCTGGG
TTCCC
Pbx2
GAGCTCACAACATGGCAGGGAGA
GTGGG
GCTAGCCAGGGGAAAAAGAAATA
TCTTTAT
Six4
GAGCTCTGCCTCTGCCTTCCAAG
TACCG
GCTAGCGATATTCTGCCACGTGAA
CTCC
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of the pmiRGLO dual luciferase vector (Promega). The primers used are listed in Table
2.4. The integrity of all constructs was verified by Sanger sequencing. Dual luciferase
reporter assays were performed 48 h after transfection of HEK293 (see 2.7.3.1) following
the manufacturer’s protocol and values for firefly luciferase were normalized to Renilla
luciferase and set to unity compared with scr mimics.
2.12 Total RNA isolation
2.12.1 Trizol based method
Total RNA was isolated from tissues or cells using peqGOLD TriFast™ (Peqlab) according
to manufacturer’s protocol. RNA was resuspended in 50 µl DEPC-H2O (0.1% DEPC) and
concentrations measured via a Nanodrop Spectrophotometer ND-1000 (Thermo Fisher
Scientific).
2.12.2 miRVANA kit isolation
RNA samples for RNA sequencing were isolated using the miRVana Isolation Kit (Am-
bion, Life Technologies) following the protocol for total RNA isolation. RNA integrity and
concentration was assessed using the Experion Bioanalyzer system (Bio-Rad) according
to the manufacturer’s instructions. Contaminating DNA was removed using the TURBO
DNA-free™ Kit (Ambion, Life Technologies) following manufacturer’s protocol.
2.13 Real-time quantitative RT-PCR (qPCR)
2.13.1 Reverse transcription and qPCR
1 µg of total RNA was reversely transcribed with High-Capacity cDNA RT kit (Thermo
Fisher Scientific) and amplified using TaqMan® Universal PCR-Master Mix (Thermo
Fisher Scientific) according to manufacturer’s instructions. Relative expression of target
mRNAs was adjusted for total RNA content by Hprt. TaqMan® probes used for gene
expression analysis are listed in Table 2.5. Calculations were performed by comparative
method (2-∆∆CT).
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2.13.2 MicroRNA reverse transcription and qPCR
For reverse transcription of particular miRNAs, 10 ng total RNA were reversely tran-
scribed using TaqMan® microRNA reverse-transcription (RT) kit (Thermo Fisher Scien-
tific) and TaqMan® primary and mature microRNA assays (Thermo Fisher Scientific)
according to the manufacturer’s instruction. Relative expression of target miRNAs was
adjusted for total RNA content by sno-429 expression. TaqMan® assays used for miRNA
expression analysis are listed in Table 2.5. Calculations were performed by comparative
method (2-∆∆CT).
Table 2.5: List of TaqMan® assays.
TaqMan® assay Gene name TaqMan® ID
miR-193b mmu-miR-193b 002467
miR-328 hsa-miR-328 000543
miR-365 hsa-miR-365 001020
pri-miR-193b primary mmu-miR-193b Mm03308440_pri
pri-miR-365 primary hsa-miR-365 Mm03307334_pri
sno-429 snoRNA429 001240
Adam12 a disintegrin and metallopeptidase domain 12
(meltrin alpha)
Mm00475719_m1
Adam17 a disintegrin and metallopeptidase domain 17 Mm00456428_m1
Adamts1 a disintegrin-like and metallopeptidase (repro-
lysin type) with thrombospondin type 1 motif,
1
Mm00477355_m1
Adamts9 a disintegrin-like and metallopeptidase (repro-
lysin type) with thrombospondin type 1 motif,
9
Mm00614433_m1
Adipoq adiponectin, C1Q and collagen domain contain-
ing
Mm00456425_m1
Aoc2 amine oxidase, copper containing 2 Mm00841716_m1
Aoc3 amine oxidase, copper containing 3 Mm00839624_m1
Bace1 exons 1-2 beta-site APP cleaving enzyme 1 Mm00478664_m1
Bace1 exons 3-4 beta-site APP cleaving enzyme 1 Mm01146407_m1
Bace1 exons 4-5 beta-site APP cleaving enzyme 1 Mm01146408_m1
Bace1 exons 8-9 beta-site APP cleaving enzyme 1 Mm00478671_m1
Cebpa CCAAT/enhancer binding protein (C/EBP), al-
pha
Mm00514283_s1
Cebpb CCAAT/enhancer binding protein (C/EBP), beta Mm00843434_s1
Cidea cell death-inducing DNA fragmentation factor,
alpha subunit-like effector A
Mm00432554_m1
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TaqMan® assay Gene name TaqMan® ID
Ckm creatine kinase, muscle Mm01321487_m1
Dio2 deiodinase, iodothyronine, type II Mm00515664_m1
Elovl3 elovl family member 3 Mm01194164_m1
Fabp4 fatty acid binding protein 4, adipocyte (AP2) Mm00445878_m1
Gprc5b G protein-coupled receptor, family C, group 5,
member B
Mm00458150_m1
Hprt hypoxanthine guanine phosphoribosyl trans-
ferase 1
Mm00446968_m1
Igfbp5 insulin-like growth factor binding protein 5 Mm00516037_m1
Myf5 myogenic factor 5 Mm00435125_m1
Myf6 myogenic factor 6 Mm00435127_g1
Myod1 myogenic differentiation 1 Mm00440387_m1
Myog myogenin Mm00446195_g1
Pax3 paired box 3 Mm00435491_m1
Ppara peroxisome proliferator activated receptor al-
pha
Mm00440939_m1
Pparg peroxisome proliferator activated receptor
gamma
Mm01184322_m1
Ppargc1a peroxisome proliferative activated receptor,
gamma, coactivator 1 alpha
Mm01208835_m1
Runx1t1 runt-related transcription factor 1; translocated
to, 1 (cyclin D-related)
Mm00486771_m1
Tnnt3 troponin T3, skeletal, fast Mm01268863_m1
Ucp1 uncoupling protein 1 Mm01244861_m1
2.14 RNA sequencing
RNA sequencing was performed at the Cologne Center for Genomics (CCG, Cologne,
Germany) headed by Prof. Peter Nürnberg. 1 µg of total RNA (2.12) was used. cDNA
libraries were prepared from poly-A-selected RNA applying the Illumina TruSeq protocol
for mRNA. Libraries were amplified with 14 cycles of PCR, pooled, quantified through
qPCR and sequenced with a 2×100 bp paired-end protocol, resulting in 30-43 million
paired reads per sample. Details on RNA QC, library preparation and data analysis were
described in [176]. Raw data for the RNA sequencing were deposited within GEO under
accession no. GSE69913.
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2.15 Protein biochemistry
2.15.1 Protein isolation
Indicated tissues or pelleted cells were lysed in RIPA buffer. For tissues an Ultra-Turrax
homogenizer (IKA Werke) was used. RIPA buffer was composed of 50 mM Tris-HCl pH
7.5, 150 mM NaCl, 1% Nonidet P-40, 500 mM EDTA, 0.1% sodium deoxycholate, 0.2 M
β-glycerol phosphate and 1 protease inhibitor tablet (cOmplete, Roche Diagnostics) for
10 ml of buffer. The samples were then snap-frozen in liquid nitrogen and thawed on ice
for three repeated cycles. After 10 min of centrifugation at 13,000 rpm supernatant was
transferred to fresh tubes and kept at -80 °C for long term storage.
2.15.2 Western blot (WB) analysis
Samples were separated by SDS-PAGE after being mixed 1:4 with 4× Laemmli Sample
Buffer (Bio-Rad) containing 10% β-mercaptoethanol and heated to 95 °C for 5 min.
PageRuler™ Prestained Protein Ladder (ThermoScientific) was used as standard.
Table 2.6: List of antibodies.
Protein target Product no. Supplier Dilution
Aoc3 C-term ab181168 AbCam 1:1000
Aoc3 N-term ab187202 AbCam 1:1000
Bace1 ab2077 AbCam 1:1000
Bace1 SAB 2106747 Sigma 1:1000
Bace1 B0681 Sigma 1:1000
Cebpa sc 61 Santa Cruz 1:200
Egfr sc 03 Santa Cruz 1:200
Hsc70 sc 7298 Santa Cruz 1:10000
Pdgrfb ab 32570 AbCam 1:5000
Pparg 07 7466 Millipore 1:1000
Ucp1 sc 6528 Santa Cruz 1:200
2.16 Southern blot (SB) analysis
2.16.1 Gel electrophoresis and blotting
Bruce 4 (Br4) ES cells transfected with LSL-Bace1 and Bace1-flox plasmids were gene-
rated in-house by the laboratory headed by Dr. Thomas Wunderlich.
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Genomic DNA (5-10 µg) derived from transfected ES cells was digested with high
concentrated EcoRI-HF (NEB) for LSL-Bace1 or high concentrated NheI-HF (NEB) for
Bace1-flox. Br4 ES cell DNA served as a wild-type control. Digested DNA was loaded
with loading dye onto a 0.8% agarose gel and separated at 30 V over night. The DNA
was then depurinated by incubating the gel in 0.25 M HCl for 20 min while shaking. The
DNA was then transferred onto a charged Amersham Hybond-XL nylon membrane by
alkaline capillary transfer over night using a sodium hydroxide solution (0.4 M NaOH)
to transfer the DNA from the gel to the membrane. The membrane was then incubated
in 2× SSC for 20 min and dried at 80 °C for 45 min to fix the DNA.
2.16.2 Probe labeling and hybridization
For SB of LSL-Bace1, a 1.2 kb ROSA26 probe was amplified from the Orkin-plasmid [177]
by EcoRI/ BamHI (NEB) restriction. For SB of Bace1-flox, a 636 bp probe was amplified
from Br4 ES cells DNA using the primers 5’ - tcatctccaccctctctcca - 3’ and 5’ - tagcctgagtat-
gacgccag - 3’. Subsequently DNA gel extraction was performed as described in 2.10. The
generated probes were radioactively labeled with 2.5 µCi[α32P]dCTP (Amersham) using
the Ladderman™ Labeling Kit (Takara). After addition of 10 mM TE buffer (pH 8.5),
the probe was further purified by spin-column chromatography using illustra MicroSpin
S-200 HR columns. After moistening in 2× SSC, the membrane was pre-hybridized
with sperm DNA in Southern blot pre-hybridization buffer at 65 °C for at least 4 h, to
prevent binding of the Southern blot probe to areas with no DNA. Radioactive probes
in pre-hybridization buffer were incubated overnight at 65 °C. After washing steps, the
membrane was placed on Kodak MS hypersensitive films in film cassettes containing an
intensifying screen over night to detect the radioactive signal. Expected DNA products
were as follows:
LSL-Bace1
WT: ~15.6 kb
Tg: ~7.1 kb
Bace1-flox
WT: ~12.6 kb
flox: ~16.8 kb
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2.17 Immunohistochemistry
Immunohistochemistry was performed by the facility within our institute (Max-Planck
Institute for metabolism research). Indicated tissue samples were incubated at 4 °C
overnight in 4% paraformaldehyde, embedded in paraffin (FFPE) and sliced according to
standard protocols. Haematoxylin and eosin (H&E) staining and insulin immunohisto-
chemistry were carried out after deparaffination as previously described in [176]. A Zeiss
Axioskop 40microscope (Carl Zeiss MicroImaging) and Zeiss AxioVision 4.2 software
(Carl Zeiss MicroImaging) were used for imaging and quantification of slides.
2.18 Cell surface capturing (CSC) analysis
CSC was performed in collaboration with the ETH proteomics facility (Zürich, Switzer-
land) headed by Prof. Bernd Wollscheid.
2.18.1 Capture of cell surface glycoproteins
For each of the three replicates, C2C12 or C2C12∆Bace1 cells of three fully confluent 15
cm dishes were washed two times with cold labelling buffer (LB; PBS pH 6.5). Cells
were mildly oxidized with 2.5 mM sodium periodate in 5 ml LB for 15 min at 4 °C in the
dark. Oxidized cells were washed with 10 ml LB and incubated in 5 ml LB containing
5 mM biocytin-hydrazide and 5 mM 2-Amino-5-methoxybenzoic acid for 20 min at 4
°C in the dark to biotinylate cell surface glycoproteins. Labelled cells were washed two
times with cold PBS and harvested by scraping. After centrifugation at 300 g for 5 min,
supernatant was removed and cell pellet resuspended in 800 µl lysis buffer (50 mM
AmBic, 0.05% RapiGest, 2 mM TCEP). Cells were lysed by sonication in a VialTweeter
(Hielscher Ultrasonics GmbH) 3 × 30 sec (0.8 s cycle time and 100% amplitude) with
intermitted vortexing and cooling on ice. Cell debris were settled down by centrifugation
at 10’000 g for 10 min, supernatant collected and protein concentration determined using
Pierce 660 nm protein assay (Thermo Fisher Scientific). Iodoacetamide was added to
a final concentration of 10 mM and lysate incubated in the dark for 30 min at room
temperature. Calcium chloride was added to a final concentration of 1 mM and proteins
digested into peptides overnight at 37 °C by adding trypsin in an enzyme:protein mass
ratio of 1:200. Trypsin was inactivated by adding PMSF to 2 mM final concentration and
acidification to pH < 3 with 10% formic acid. Digested protein lysate was centrifuged
at max. speed for 15 min and peptide concentration of supernatant measured with
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a NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific). Per replicate, 15 mg
peptide were subjected to automated purification of cell surface biotinylated glycopeptides.
For this, in-house packed tips containing 80 µl streptavidin resin were hooked to a
Versette liquid handling robotic system (Thermo Fisher Scientific) and incubated with
the digested cell lysate for 1 h at room temperature with up-and-down pipetting. In
an automated fashion, bead-bound peptides were subsequently washed with 5 M NaCl,
StimLys Buffer (50 mM Tris pH 7.8, 137 mM NaCl, 150 mM Glycerol, 0.5 mM EDTA,
0,1% Triton X-100), 100 mM NaHCO3 and 50 mM NH4HCO3 (AmBic). Beads were
further incubated overnight at 37 °C with 600 µl AmBic containing 1000 units PNGase
F to specifically release formerly N-glycosylated peptides. Eluted peptides were acidified
to pH < 3 by formic acid and subjected to C18 purification using 3-30 µg UltraMicroSpin
Columns (The Nest Group) according to manufacturer’s instructions.
2.18.2 LC-MS and data analysis
Peptides were reconstituted in 3% acetonitrile (ACN) with 0.1% formic acid (FA) and sepa-
rated by reversed-phase chromatography on a high-performance liquid chromatography
(HPLC) column (75-µm inner diameter, New Objective) that was packed in-house with
a 15-cm stationary phase (ReproSil-Pur C18-AQ, 1.9 µm) and connected to a nano-flow
HPLC combined with an autosampler (EASY-nLC 1000, Thermo Fisher Scientific). The
HPLC was coupled to a Q-Exactive plus mass spectrometer (Thermo Fisher Scientific)
equipped with a nano electrospray ion source (Thermo Fisher Scientific). Peptides were
loaded onto the column with 100% buffer A (99.9% H2O, 0.1% FA) and eluted at a
constant flow rate of 300 nl/min with a 70-min linear gradient from 6-28% buffer B
(99.9% ACN, 0.1% FA) followed by a 4-min transition from 28 to 50% buffer B. After
the gradient, the column was cleaned for 18 min with two steep consecutive gradients
of ACN (10%-98%). Electrospray voltage was set to 2 kV, sheath and auxiliary gas
flow to zero and capillary temperature to 250 °C. Following a high-resolution survey
mass spectrum (from 300 to 1,700 m/z) acquired in the Orbitrap with resolution R =
70,000 at m/z 200 (automatic gain control target value 3×106), the 15 most abundant
peptide ions with a minimum intensity of 2.5×104 were selected for subsequent HCD
fragmentation with an isolation window of 1.4 Da and fragments were detected in the
Orbitrap at resolution R = 35,000 (automatic gain control target value 1×106). Targeted
ion masses already selected for fragmentation were dynamically excluded for 30 se-
conds. Acquired raw files were subjected to peptide and protein identification using
the Trans Proteomic Pipeline v.4.7 [178]. First, fragment ion spectra were matched
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against a database of SwissProt (UniProt consortium) reviewed mouse protein sequences
(downloaded April 2014) and common contaminants. Peptides were required to have
one tryptic cleavage terminus (semitryptic) with a maximum of 2 missed cleavage sites
and carbamidomethylation as a fixed modification. Methionine oxidation and PNGase F
mediated asparagine deamidation were set as dynamic modifications. The precursor and
fragment mass tolerance was set to 20 ppm and 0.02 Da, respectively. Identified proteins
were quantified by integration of chromatographic traces of their corresponding peptides
on MS1 level using Progenesis QI v.2.0 (Nonlinear Dynamics, UK). Contaminant hits
were removed and proteins filtered to obtain a false discovery rate of < 1%. Raw protein
abundances based on non-conflicting peptides were exported. Proteins with at least one
transmembrane domain and an asparagine deamidation modification within the common
N-X-S/T glycosylation motif were considered as bona fide cell surface glycoproteins and
were subjected to differential abundance testing using R-package MSstats v3.2.2 [179].
Proteins with an abundance fold change of ± 1.5 and adjusted p-value < 0.05 indicate
significantly regulated proteins upon perturbation.
2.19 Improved secretome protein enrichment with
click sugars (iSPECS)
iSPECS was performed in collaboration with the laboratory of neuroproteomics at the
German Center for Neurodegenerative Diseases (DZNE, Munich, Germany) headed by
Prof. Stefan Lichtenthaler.
For each of the six replicates, C2C12 or C2C12∆Bace1 cells were seeded in 6-well plates.
When fully confluent (∼ 1.5 million cells), cells were first washed with PBS and then
maintained in growth medium supplemented with 50 µM ManNAz sugar dissolved in
DMSO. After 48 h supernatants were filtered through 0.2 µM filters, stored at -20 °C
and later sent to our collaborators on dry ice. iSPECS proteomic analysis was performed
using an unpublished protocol based on the SPECS technique described in [180] [181].
2.20 MicroRNA gene target overlap
Overlap between target genes of each pair of mouse microRNAs was calculated using the
Targetscan algorithm (http://www.targetscan.org). Applying this procedure to all possible
pairs, resulted in a representation of the probability density function of the overlap size.
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Finally, p value for a particular pair of microRNAs was computed by comparing the size
of their target overlap with this distribution.
2.21 Ingenuity pathway analysis (IPA)
For pathway analysis of RNA sequencing (2.14) results, the 2,000 most changed genes
were shortlisted using the Ingenuity Pathway Analysis software (IPA, Ingenuity Sys-
tems). Overrepresented gene ontology (GO) pathways were visualised using the IPA
suite.
2.22 Graphical representation of data and statistical
analysis
All graphs were created using GraphPad Prism 6.0 (GraphPad Software). Floating bars
indicate minimum, maximum and mean values. GraphPad Prism 6.0 software was used
to perform statistical calculations. When two groups were analysed, significance was
determined using an unpaired or paired Student’s t-test. One-way ANOVA followed by
Bonferroni correction was used when three groups were analysed. Two-way ANOVA for
repeated measures (2WA-RM) followed by Bonferroni post-hoc test was used to judge the
effect of two independent variables. Statistical details are given in the figure legends. A
p value < 0.05 is considered statistically significant.
n.s. p >0.05
* p <0.05
** p <0.01
*** p <0.001
**** p <0.0001
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2.23 Utilised chemicals
Table 2.7: Chemicals
Chemical Supplier
0.9% Saline (sterile) AlleMan Pharma GmbH
3-Isobutyl-1-methylxanthin (IBMX) Sigma-Aldrich
3,3’,5-Triiodo-L-thyronine (T3) Sigma-Aldrich
Acrylamide Roth
Agarose Peqlab
Agarose (Ultra Pure) Invitrogen
Ammoniumpersulfat (APS) Sigma-Aldrich
Ampicillin Sigma-Aldrich
Bacillol Bode Chemie
Biocytin-hydrazide Pitsch NucleicAcids
Bovine serum albumin (BSA) Sigma-Aldrich
Chloroform Merck
D(+)-Glucose-Monohydrat AppliChem
DEPC AppliChem
Developer G153 AGFA
Dexamethasone Sigma-Aldrich
Dimethylsulfoxide (DMSO) Merck
dNTPs Set, 100 mM Solutions Thermo Fisher Scientific
Dulbecco’s Phosphate Buffered Saline (DPBS) Thermo Fisher Scientific
Enhanced chemiluminescence (ECL) Kit Perbio Science
Ethanol, absolute AppliChem
Ethidium bromide Sigma-Aldrich
Ethylendiamine tetraacetate (EDTA) AppliChem
Fixer G354 AGFA
Formamide AppliChem
GeneRuler DNA Ladder Mix Thermo Fisher Scientific
Glucose 20% DeltaSelect
Glycerol-free PNGase F New England Biolabs
Hydrochloric acid (37%) KMF Laborchemie
Indomethacin Sigma-Aldrich
Insulin Novo Nordisk
Isopropanol (2-propanol) Roth
Click-IT™ ManNAz Thermo Fisher Scientific
Methanol Roth
Nitrogen (liquid) Linde
Nonidet P-40 Roche Diagnostics
OPTI-MEM (1×) Thermo Fisher Scientific
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Chemical Supplier
Paraformaldehyde (PFA) Sigma-Aldrich
Quick Start™ Bradford dye reagent Bio-Rad
RapiGest SF Surfactant Waters
Rosiglitazone Sigma-Aldrich
Rotiphorese® Gel 30 (37,5:1) Roth
Sequencing Grade Modified Trypsin Promega
Sodium chloride (NaCl) AppliChem
Sodium deoxycholate Sigma-Aldrich
Sodium dodecyl sulfate AppliChem
Streptavidin Plus UltraLink Resin Thermo Fisher Scientific
Tetramethylethylenediamine (TEMED) Sigma-Aldrich
Tissue Freezing Medium Jung
Trishydroxymethylaminomethane (Tris) AppliChem
Trypsin-EDTA (10×) Thermo Fisher Scientific
Tween 20 AppliChem
Western Blocking Reagent Roche Diagnostics
β-glycerophosphate disodium salt hydrate Sigma-Aldrich
β-mercaptoethanol AppliChem
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PRELIMINARY DATA
Our group could show that brown fat-specific heterozygous knock-out of Dicer in micewas associated with deterioration of glucose metabolism [170]. This was aggravated
under obese condition and was likely dependent on decreased EE due to reduced BAT
activity and function [170]. In light of these findings, we investigated which specific miR-
NAs were involved in the regulation of brown adipocyte homeostasis. Using microarray
analysis, we quantified the expression of miRNAs during adipogenic differentiation of
primary immortalised brown adipocytes (PIBAs), a stable cell line of brown-programmed
pre-adipocytes (Figure 3.1 a). To examine both in vitro and in vivo miRNA regulation,
we also investigated the expression of these noncoding RNAs in mouse models of altered
BAT function. For this purpose we analysed BAT samples from mouse models of diet-
induced obesity (DIO) via high-fat diet (HFD) feeding, premature ageing in progeroid
Ercc1-/- mice and long-lived homozygous Ames dwarf mutants (Amesdf). The first two
conditions are known to have detrimental effects on BAT [182] [183], while the latter is
known to enhance BAT function [184]. We selected miRNAs up-regulated during PIBA
commitment and in BAT of Amesdf mice and decreased in brown fat of DIO and progeroid
mice, finding 23 miRNAs fulfilling these criteria (Figure 3.1 b). Of these we selected
eight for further in vitro characterisation, namely miR-96, miR-210, miR-328 and all
five miR-30 family members (miR-30a-e), some of which have already been shown to
play a role in BAT homeostasis (1.5.4.1). We could validate the microarray results on
qPCR level showing an increased expression during PIBA differentiation and a down-
regulation upon HFD feeding for all the miRNA candidates (Figure 3.1 c). We then
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FIGURE 3.1. MiR-328 regulates brown adipose tissue differentiation in vitro. a Heat-
map diagram illustrating expression of miRNAs in differentiating PIBA cells at indicated
time points. For each time-point, miRNA expression levels in three PIBA samples were
quantified using an independent qPCR array each. b Venn diagram depicting overlap
of miRNA expression in the four indicated conditions. c Relative expression of indicated
miRNAs during PIBA differentiation (left) or in BAT from HFD-fed (n=6) versus NCD-fed
(n=6) mice (right). d Representative Oil Red O staining of differentiated PIBAs seven days
after transfection with LNAs against indicated miRNAs versus scramble (scr) controls.
Image is representative of three independent experiments. e Expression of indicated genes
in differentiated PIBA cells seven days after transfection with LNAs against indicated
miRNAs versus scr controls. Experiments were performed in triplicate and represent the
average of two/three independent experiments. *p<0.05, **p<0.01.
assessed the effects of inhibition of these miRNAs on the adipogenic differentiation of
PIBA cells. For this purpose we utilised miRCURY LNA™ Power Inhibitors and selected
miR-193b, previously shown to regulate brown adipocyte fate [168] and present in our
list of differentially expressed miRNAs (Figure 3.1 a), as internal control. We could
observe an impairment in the differentiation of PIBA cells upon miR-193b and miR-328
inhibition, as shown by decreased lipid accumulation (Figure 3.1 d). These results were
supported by decreased expression of BAT-specific genes in PIBAs treated with LNAs
against miR-193b and miR-328 (Figure 3.1 e).
Taken together our results identified miR-328 as a novel regulator of brown fat com-
mitment in vitro and confirmed previous reports on the in vitro regulation of brown
adipocytes by miR-193b.
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RESULTS
4.1 Dicer1 regulation of brown adipose tissue
4.1.1 Metabolic analysis of Dicer1∆BAT/+ mice
Hormone level analysis
Dicer1∆BAT/+ mice showed decreased glucose tolerance in both males and females already
under NCD condition [170]. When fed a HFD, this defect in glucose homeostasis was
even more pronounced and was associated with decreased insulin sensitivity. In order
to understand if this decline in glucose metabolism was due to hormone impairment
we analysed the plasma levels of the adipocyte hormone leptin and of the pancreatic
hormone insulin in both sexes and diet conditions. ELISA analysis showed no difference
in hormone levels in the plasma of Dicer1∆BAT/+ mice compared to control littermates
(Figure 4.1 a and b).
Adiposity analysis
Although HFD-fed Dicer1∆BAT/+ mice showed an increase in adiposity [170], we could not
observe any macroscopical sign of body fat redistribution as published for pan-adipose
Dicer1-null mice by Mori et al. [151]. To assess whether the fat redistribution occurred
merely on a microscopical level we performed plasma lipid and immunohistochemical
analyses in Dicer1∆BAT/+ mice fed a HFD diet. However, thin-layer chromatography
(TLC)-mediated quantification of cholesterol, free fatty acids and triglycerides in liver
and muscle (Figure 4.1 c) revealed no alteration in lipid concentrations in knock-out
mice.
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FIGURE 4.1. Dicer1 regulation of brown adipose tissue. a Serum insulin level of NCD-
fed, male Dicer1∆BAT/+ (n=9) versus control mice (n=10) and HFD-fed, male Dicer1∆BAT/+
(n=5) versus control mice (n=8, left) or NCD-fed, female Dicer1∆BAT/+ (n=8) versus control
mice (n=9) and HFD-fed, female Dicer1∆BAT/+ (n=5) versus control mice (n=12, right). b Se-
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rum leptin level of NCD-fed, male Dicer1∆BAT/+ (n=10) versus control mice (n=9) and HFD-fed,
male Dicer1∆BAT/+ (n=7) versus control mice (n=13, left) or NCD-fed, female Dicer1∆BAT/+
(n=9) versus control mice (n=9) and HFD-fed, female Dicer1∆BAT/+ (n=10) versus control
mice (n=11, right). c Thin-layer chromatography-mediated quantification of lipid species
(Chol, cholesterole; FFA, free fatty acids; TG, triglycerides) in indicated tissues of HFD-fed
Dicer1∆BAT/+ (n=5) versus control (n=6) mice. d Photomicrograph of indicated tissues in
HFD-fed Dicer1∆BAT/+ and control mice. A representative image is shown. e Immunoblot
of UCP1 expression in BAT of Dicer1∆BAT/+ (n=9) versus control (n=10) mice. Image is
representative of two independent experiments (top). Densitometric quantification of protein
levels in Dicer1∆BAT/+ mice (n=9) versus controls (n=10). Relative levels for control mice were
set to unity=1 (bottom) f Relative expression of indicated primary (pri-) and mature microRNAs
in BAT of male Dicer1∆BAT/+ (n=8) versus control (n=8) mice. *p<0.05, ***p<0.001, ****p<0.0001.
Furthermore, comparison of H&E stainings of the three main adipose depots and liver of
Dicer1∆BAT/+ mice with littermate controls indicated no redistribution of body fat (Figure
4.1 d).
Moreover, we examined whether the inability of lean Dicer1∆BAT/+ mice to maintain core
body temperatures under thermal stress (4 °C) was correlated with molecular defects
in thermogenic markers. For this purpose we analysed the protein levels of uncoupling
protein 1 (Ucp1) in BAT of Dicer1 deficient mice. Our results showed a decrease in UCP1
protein in Dicer1∆BAT/+ mice compared to controls (Figure 4.1 e), further supporting a
thermogenic impairment in these mice.
These experiments suggest that Dicer1 deficiency specifically in BAT does lead to an
obesity-associated impairment in both glucose homeostasis and thermogenesis without
causing ectopic fat deposition or lipodystrophy [151].
4.1.2 MicroRNA processing is impaired in brown fat of
Dicer1∆BAT/+ mice
DICER1 is one of the key regulators of miRNA processing, generating miRNA duplexes
through cleaving of pre-miRNAs in the cytoplasm prior to mature miRNAs generation
(1.5.2). Dicer1∆BAT/+ mice were generated by depletion of the gene from one of the two
DNA alleles [170]. Since the heterozygous Dicer1 knock-out in BAT resulted in a mere
25% decrease of Dicer1 mRNA, we investigated whether the ratio of mature miRNAs
over pri-miRNAs was affected. We selected two miRNAs (miR-193b and miR-365) for
expression analysis of both primary and mature sequences. As seen in Figure 4.1 f only
mature forms of miR-193b and miR-365 were decreased, indicating a specific effect of
Dicer1 knock-out on mature miRNAs only.
We could hereby confirm a successfully established defect in miRNA maturation that
might account for the thermogenic phenotype we observed in Dicer1∆BAT/+ mice.
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4.2 MiR-328 regulates the switch between brown
adipose tissue and muscle
4.2.1 Localisation analysis of miRNA candidates
As shown in chapter 3 our laboratory discovered miR-328 as BAT-related miRNA whose
expression is regulated in mouse models of obesity and ageing. In addition miR-328
was shown to affect differentiation of brown preadipocytes (Figures 3 d and e). For an
overview of the tissue distribution of miR-193b and miR-328, expression of the two
miRNAs was analysed on a transcript level in metabolic-related tissues (brown and
white adipose tissue, skeletal and cardiac muscle and liver, Figure 4.2 a). qPCR analysis
revealed an enrichment of miR-193b and miR-328 in BAT and WAT, supporting a po-
tential role of these in adipose tissue regulation. These results are in line with previous
studies depicting these miRNAs as highly enriched in murine and human BAT [163].
Given the enrichment of miR-193b and miR-328 brown adipose tissue and the regula-
tion of miR-328 specifically on brown adipogenesis in vitro, we decided to determine
the expression levels of miR-193b and miR-328 in our in vivo model for BAT-specific
Dicer1 deficiency. As expected the miRNA candidates showed a decreased expression in
Dicer1∆BAT/+ mice compared to littermate controls (Figure 4.2 b).
The defect in thermogenesis and glucose homeostasis observed in Dicer1∆BAT/+ mice
could hence also be linked to the reduction of miR-193b and miR-328.
4.2.2 MiR-193b/miR-328 deficiency stimulates myogenic marker
expression
Skeletal myoblasts and brown adipocytes derive from a common cell lineage (1.3.2) and
modulation of transcriptional factors like PRDM16 [70] can control a bidirectional cell
fate switch between the two tissues. We therefore investigated the expression of myogenic
markers in PIBA cells and in the mouse myoblast C2C12 cell line upon miR-193b and
miR-328 knock-down. Deficiency of both miRNAs showed an increase in the expression of
paired box 3 (Pax3) and RUNX1 translocation partner 1 (Runx1t1) in PIBA cells and the
same expression pattern could be observed in C2C12 cells exclusively upon knock-down
of miR-328 (Figure 4.2 c).
As miR-193b and - even more potently - miR-328 knock-down could enhance a myogenic
phenotype in both skeletal myoblasts and brown adipocytes, we examined whether the
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FIGURE 4.2. MiR-328 regulates the switch between brown fat and muscle. a Relative
expression of miR-193b and miR-328 in n=8 indicated tissues (BAT, brown adipose tissue;
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H, heart; L, liver; SM, skeletal muscle; WAT, white adipose tissue). Expression levels in BAT
were set to unity=1. b Relative expression of indicated microRNAs in BAT of male Dicer1∆BAT/+
(n=8) versus control (n=8) mice. c Relative expression of indicated genes in PIBA (left) or C2C12
(right) cells transfected with scr, miR-193b or miR-328 LNAs. d Immunoblots against indicated
proteins after transfection of PIBA cells with LNAs against miR-328 versus scr. Image is
representative of three (UCP1) or two (others) independent experiments. e Relative expression
of indicated genes in PIBA cells transfected with scr, miR-193b or miR-328 mimics. f Oxygen
consumption rates (OCR) of PIBA cells transfected with scr, miR-193b or miR-328 mimics
(left). Illustration of maximal OCR at measurement 7 (arrow, right). The data shown are from
measurements in at least 14 wells for each condition. g Relative expression of indicated genes
in 3T3-L1 cells after transfection with LNAs against indicated miRNAs versus scr controls
or miRNA mimics versus scr. Experiments were performed in triplicate and represent the
average of three independent experiments. h Immunoblots against indicated proteins after
transfection of 3T3-L1 cells with miRNA LNAs versus scr or miRNA mimics versus scr. Image
is representative of two independent experiments. *p<0.05, **p<0.01, ***p<0.001.
knock-down would likewise cause a reduced adipogenic phenotype. We could indeed show
a decrease in protein expression of BAT-specific UCP1 together with increased expression
of WAT markers like CCAAT/enhancer binding protein (C/EBP) alpha (CEBPα) and
peroxisome proliferator activated receptor gamma (PPARγ) after miR-328 silencing in
PIBA cells (Figure 4.2 d).
These results point to a decrease in BAT activity upon miRNA candidates depletion,
possibly due to increased myogenic potential or whitening (1.3.1) of brown fat.
4.2.3 MicroRNA over-expression in PIBAs stimulates
adipogenic features
Given the reduced thermogenic activity of brown adipocytes upon LNA-based knock-down
of miR-193b and miR-328, we hypothesized that an over-expression of these miRNAs
could potentially trigger a therapeutically desirable increase in BAT activity. For this
purpose we transfected miRIDIAN microRNA mimics, which supplement endogenous
miRNA activity, in PIBA cells. Notably, both miR-193b and miR-328 over-expression
increased gene expression of Cebpb and Ucp1 (Figure 4.2 e). On a functional level, both
over-expression models caused elevated oxygen consumption rates (OCRs), a metabolic
hallmark of activated brown fat cells (Figure 4.2 f).
We could hereby prove, that miR-193b and miR-328 over-expression is positively corre-
lated with thermogenic activity.
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4.2.4 White adipose tissue cell line is not affected by miR-328
expression
As we hypothesized that miR-328 activity on cell fate decision is specific for the cell
lineage which gives rise to myocytes and brown - but not white - adipocytes, we decided
to test the effects of our gain- and loss-of-function models in the white adipogenic 3T3-L1
cell line (Details in 2.7.5). Both mRNA (Figure 4.2 g) and protein expression (Figure 4.2
h) of adipogenic markers like Cebpa and Pparg were unaltered in LNA knock-down and
mimic over-expression experiments, supporting a BAT-specific effect of miR-328.
We thus confirmed miR-328 to have a role in the regulation of myogenic and brown - but
not white - adipogenic homeostasis.
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4.3 Bace1 and Gprc5b as novel targets of miR-328
4.3.1 MiR-193b and miR-328 share common target genes
MicroRNAs are key regulatory RNAs known to repress mRNA translation via base-
pairing of their seed sequence with complementary sequences present mainly in the
3’-UTR of targeted mRNA molecules (1.5.2). As shown in 3.1 our group confirmed miR-
193b and newly discovered miR-328 to support brown preadipocyte differentiation and
skew muscle progenitor cells towards a brown fat transcriptional profile. Considering
the inhibitory role of miRNAs we decided to look for potential targets of these two
miRNAs that could have an effect on peripheral tissue metabolism. Strikingly, we
observed notable sequence similarities between the seed regions of miR-193b and miR-
328, thus resulting in a significant overlap of common predicted target genes (Figure 4.3
a). This consequently suggests that the two miRNAs might control brown adipogenesis
by regulating the same pool of mRNAs via expression silencing. Using in silico prediction
(www.microRNA.org), we selected nine predicted common target genes between miR-
193b and miR-328. The criteria used for this selection included genes harbouring binding
sites for both miRNAs in their 3’-UTR and genes enriched in muscle as shown through
publicly available expression profiles (www.biogps.org). The nine selected target genes
were then validated by luciferase reporter assay. For this, the firefly luciferase open
reading frame was cloned upstream of the 3’-UTRs of putative target genes. HEK293
transfection of the generated vectors revealed that over-expression of miR-193b and miR-
328 down-regulated the luciferase activity of two transcripts (Figure 4.3 b): β-site amyloid
precursor protein cleaving enzyme 1 (Bace1), known for its role in the development of
Alzheimer’s disease (AD), and G-protein coupled receptor family C group 5 member B
(Gprc5b). Bace1 was reported to be potentially targeted by miR-328 in neuronal cells
[185].
4.3.2 Bace1 and Gprc5b are direct targets of miR-193b and
miR-328
To asses if the aforementioned decrease in luciferase activity seen for Bace1 and Gprc5b
occurred exclusively due to base-pairing of miR-193b and miR-328 to the 3’-UTR of the
two genes, we mutated the predicted miRNA seed sequences. The seed mutation did
indeed abrogate the effect of microRNA over-expression on Bace1 and Gprc5b in the
luciferase reporter assay (Figure 4.3 c). Furthermore, LNA-mediated down-regulation
and mimic-mediated over-expression of miR-193b and miR-328 in PIBA cells correlated
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FIGURE 4.3. Bace1 and Gprc5b as novel targets of miR-328. a Comparison of miR-193b
versus miR-328 seed sequences (top) and overlap of in silico predicted miR-193b and
miR-328 mRNA targets (bottom). b Relative luciferase activity in HEK293 cells after
co-transfection of pmiRGlo reporter constructs harbouring wild-type 3’UTR fragments
of indicated genes together with scr, miR-193b or miR-328 mimics. c Relative luciferase
activity in HEK293 cells after co-transfection of pmiRGlo reporter constructs harbouring
wild-type (wt) or mutated (mut) 3’UTR fragments of indicated genes together with scr,
miR-193b or miR-328 mimics. d Immunoblot analysis of BACE1 in PIBA cells transfected
with scr, miR-193b or miR-328 mimics (top) or LNAs (bottom). Image is representative of
two (mimics) or three (LNAs) independent experiments. e Relative expression of Bace1
(n=6) and Gprc5b (n=8) in indicated tissues (BAT, brown adipose tissue; H, heart; L, liver;
SM, skeletal muscle; WAT, white adipose tissue). Expression levels in BAT were set to
unity=1. *p<0.05.
with protein expression of Bace1 (Figure 4.3 d). To analyse tissue distribution of Bace1
and Gprc5b we performed qPCR analysis in BAT, heart, liver, SM and WAT. We found
Bace1 to be enriched in the two muscle tissues while Gprc5b is enriched in BAT and SM
(Figure 4.3 e).
These results indicate Bace1 and Gprc5b as direct targets of miR-193b and miR-328 that
could potentially regulate adipose tissue and muscle metabolism.
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4.4 Bace1 deficiency in vitro promotes brown
adipogenesis while inhibiting myogenesis
4.4.1 Bace1 but not Gprc5b knock-down inhibits late
myogenesis of C2C12 cells
Depletion of miR-193b and miR-328 in vitro attenuated myogenic potential. To asses
whether Bace1 and Gprc5b act downstream of miR-193b and miR-328 in regulating
myogenesis and brown adipogenesis in vitro, we examined the effects of the inhibition of
these genes in C2C12 cells. Bace1 and Gprc5b inhibition was obtained using Antisense
LNA™ GapmeRs (Exiqon) and validated via qPCR (Figure 4.4 a and d).
Gprc5b silencing in C2C12 cells during the course of myogenic differentiation showed no
effect on cell morphology or myogenic marker expression (Figure 4.4 b and c). Knock-down
of Bace1 transcript levels on the other hand caused morphological defects in myogenesis
(Figure 4.4 b) and a concomitant reduction in late - but not early - myogenic marker
expression, such as creatine muscle kinase (Ckm), myogenin (Myog) and troponin T type
3 (Tnnt3) (Figure 4.4 c).
Thus we concluded that the enhanced myogenic phenotype upon silencing of miR-193b
and miR-328 is likely to occur due to direct inhibition of Bace1 but not Gprc5b mRNA.
4.4.2 Bace1 down-regulation promotes brown adipocyte
differentiation and activity in vitro
Silencing of miR-193b and miR-328 did not only result in increased myogenic potential
in myoblasts and brown adipocytes, but also in a reduction of thermogenesis in PIBA
cells. We hence hypothesized that Bace1 as direct target of miR-193b and miR-328 may
not only affect myogenesis but also brown adipogenesis. In fact, Bace1 knock-down in
PIBA cells accelerated lipid accumulation (Figure 4.4 e) and augmented the expression
of brown fat-specific markers as elongation of very long chain fatty acids-like 3 (Elovl3),
peroxisome proliferator activated receptor alfa (Ppara), Pparg and Ucp1 (Figure 4.4 f).
This effect was not observed in the white adipocyte cell model 3T3-L1 (Figure 4.4 g).
Furthermore, Bace1 inhibition in PIBA cells increased oxidative metabolism as indicated
by higher OCRs detected for maximal cellular respiration (Figure 4.4 h).
Taken together our results indicate a role for Bace1 inhibition by miR-193b and miR-328
in supporting brown - but not white - adipogenesis to the detriment of myogenesis.
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FIGURE 4.4. Bace1 deficiency in vitro promotes brown adipogenesis while inhibit-
ing myogenesis. a Relative expression of Bace1 and Gprc5b in C2C12 cells 2 days after
transfection with indicated LNA GapmeRs. b Photomicrograph of C2C12 cells after trans-
fection with indicated LNA Gapmers. Image is representative of three independent experi-
ments. c Relative expression of indicated genes in C2C12 cells transfected with indicated
LNA GapmeRs. d Relative expression of Bace1 in PIBA cells 2 days after transfection
with indicated LNA GapmeRs. Experiments were performed in triplicate and represent
the average of three independent experiments. e Photomicrograph of PIBA cells after
transfection with Bace1 LNA Gapmers. Image is representative of three independent
experiments. f Relative expression of indicated genes in PIBA cells transfected with Bace1
LNA GapmeRs. g Relative expression of indicated genes in 3T3-L1 cells transfected with
Bace1 LNA GapmeRs. h Oxygen consumption rates (OCR) of PIBA cells transfected with
Bace1 LNA GapmeRs (left). Illustration of maximal OCR at measurement 7 (arrow, right).
The data shown are from measurements in at least 16 wells for each condition. All qPCR
experiments were performed in triplicate and represent the average of at least three
independent experiments. *p<0.05.
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4.5 BACE1 is differentially expressed in in vivo
models of induced and impaired thermogenesis
To investigate whether the effects seen on brown adipocyte differentiation in vitro reflect
a role for BACE1 on BAT also in vivo, we analysed the expression of Bace1 in mouse
models of challenged brown fat function. We quantified the mRNA levels of Bace1 in
mice exposed to 4 °C for one or seven days, as a model for thermogenic activity, proven by
a drastic increase in BAT-specific markers Elovl3 and Ucp1 in BAT and SCAT. Results
demonstrated that upon of both BAT activation and SCAT browning, Bace1 mRNA levels
were significantly decreased (Figure 4.5 a). As a model for inactivated BAT, progeroid
(Ercc1-/-) and obese (HFD) mice were examined. Protein analysis revealed an increase
in BACE1 protein expression in BAT of both in vivo models compared to their control
littermates (Figure 4.5 b).
These results suggest that Bace1 expression is associated with the activity of BAT not
only in vitro but also in vivo.
FIGURE 4.5. BACE1 is altered in in vivo models of thermogenesis impairment. a
Relative expression of indicated genes in BAT and SCAT at ambient temperatures (22 °C)
or under thermal stress (4 °C) for indicated time periods. Four tissue samples were used
per time point/gene. b left: Immunoblot analysis of BACE1 in Ercc1-/- (n=4) mice versus
Ercc1+/+ (n=4) controls (top) or in NCD-fed (n=4) versus HFD-fed (n=4) mice (bottom).
Image is representative of two (top) or three (bottom) independent experiments. b right:
Densitometric quantification of protein levels. Relative protein levels for NCD-fed and
Ercc1+/+ control mice were set to unity=1. *p<0.05, **p<0.01, ***p<0.001.
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4.6 BACE1 inhibition in vivo ameliorates energy
homeostasis
4.6.1 Specific BACE1 inhibitor protects mice from diet-induced
obesity
To support a BAT inactivating function of BACE1 in vivo and to investigate the ther-
apeutic applicability of a BACE1 treatment, we decided to study the effects of BACE1
inhibition in obese mice with defective BAT functionality.
As described in 1.2.4, BACE1 inhibitors have been widely studied and tested in both
mice and humans given the central role of the protease in AD development. For our in
vivo studies we utilised the BACE1 inhibitor RO5508887, a small molecule generated by
Roche [43], which is able to suppress BACE1 activity of more than 85% in rodent models
and which has already been tested for potential toxicity.
We compared mice fed a HFD for 15 weeks (starting at 4 weeks of age) with mice that
after 3 weeks of HFD were fed with HFD+RO5508887. Interestingly, after only one
week mice fed with BACE1 inhibitor already gained less body weight than control mice
(Figure 4.6 a) and maintained a lower body weight throughout the experiment despite
no observed differences in food intake (Figure 4.6 b).
These data indicate that inhibition of BACE1 in vivo protects from diet-induced obesity
without reducing energy intake.
4.6.2 BACE1 inhibition enhances glucose metabolism in obese
mice
We next questioned whether the protection from diet-induced obesity upon BACE1
inhibition was linked to improved glucose homeostasis. Indeed, the decrease in body
weight gain in mice receiving RO550887-supplemented HFD was associated with an
ameliorated regulation of glucose metabolism as shown by glucose and insulin tolerance
tests (GTT and ITT in Figure 4.6 c and d respectively).
Given the high sequence homology of BACE1 and the protease BACE2 (∼75% homo-
logous, 45% identical) [186][187] and considering that BACE2 was shown to affect glucose
metabolism in vivo through increased insulin secretory capacity and pancreatic β-cell
mass [188], we investigated whether inhibition of BACE1 in our in vivo model affects in-
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FIGURE 4.6. BACE1 inhibition in vivo regulates glucose homeostasis.
a Relative body weight gains in HFD-fed (n=15) versus HFD+RO550887-fed (n=15) male
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C57BL/6 mice. b Average food intake quantified by manual recordings of HFD-fed (n=15) and
HFD+RO550887-fed (n=15) mice during the course of the feeding experiment (12 weeks). c Glu-
cose tolerance tests in HFD-fed (n=15) versus HFD+RO550887-fed (n=15) male C57BL/6 mice.
d Insulin tolerance tests in HFD-fed (n=15) versus HFD+RO550887-fed (n=15) male C57BL/6
mice. e Glucose-stimulated insulin secretion of HFD-fed (n=7) versus HFD+RO550887-fed
(n=7) mice. f Percentage of insulin-positive (ins+) cells in pancreatic sections from HFD-fed
(n=6) and HFD+RO550887-fed (n=6) mice (left). Insulin staining and H&E counterstaining
of pancreatic islets in HFD and HFD+RO550887-fed mice (right). A representative image is
shown. g Body composition measured by nuclear magnetic resonance of HFD-fed control (n=15)
versus HFD+RO550887-fed (n=14) male C57BL/6 mice. h Tissue weight/body weight (BW) ratio
of indicated tissues in HFD-fed (n=15) versus HFD+RO550887-fed (n=14) male C57BL/6 mice. i
Photomicrograph of BAT and VAT in HFD-fed and HFD+RO550887-fed male C57BL/6 mice.
A representative image is shown. j H&E staining of VAT and SCAT sections from HFD-fed
(n=5) and HFD+RO550887-fed (n=5) mice analyzed using Zeiss Axiovision 4.2 software and
adipocyte area cummulatively plotted in 10 increments. k Relative expression of indicated
genes in BAT of HFD (n=6) versus HFD+RO550887-fed (n=5) male C57BL/6 mice. l Relative
expression of indicated genes in SCAT of HFD (n=9) versus HFD+RO550887-fed (n=10) male
C57BL/6 mice. m Network illustration of changes in IPA pathways in HFD-fed (n=3) versus
HFD+RO550887-treated (n=3) male C57BL/6 mice. *p<0.05, **p<0.01, ***p<0.001.
sulin regulation in a comparable manner as BACE2. However, we observed no differ-
ences in glucose-stimulated insulin secretion (Figure 4.6 e) or pancreatic islet morphology
(Figure 4.6 f) between the two groups. Moreover, the improved insulin sensitivity upon
BACE1 inhibition (Figure 4.6 d) does not hold true for Bace2∆/∆ mice.
These findings lead to the conclusion that RO550887-mediated BACE1 inhibition im-
proves glucose homeostasis in a BACE2-independent manner.
4.6.3 BACE1 regulates body fat composition
Having proven a beneficial effect of BACE1 inhibition on whole body metabolism, we
assessed whether this phenotype may specifically be attributed to adipose tissue depots.
Interestingly, RO5508887-feeding lead to an increase in lean mass (Figure 4.6 g) and a
significant decrease of epididymal visceral adipose tissue weight (Figure 4.6 h). In order
to analyse lipid distribution in fat depots, visual and automatic analysis of adipocyte
size, for brown and white adipose tissue respectively, was performed (Figure 4.6 i and j).
Immunohistochemical analyses revealed a decrease in lipid droplet size in BAT and VAT
of RO5508887-treated mice compared to control littermates.
We could hereby show that suppression of BACE1 activity leads to smaller lipid burden
in both thermogenically active and inactive adipose tissue.
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4.6.4 RO5508887-treated mice show increased expression of
BAT markers
Given the reduced energy storage at unaltered food intake rates, we addressed whether
RO5508887-fed mice may show increased energy expenditure in form of thermogenesis.
We therefore analysed brown fat marker expression in BAT and SCAT of obese BACE1
deficient mice. qPCR results revealed that in vivo BACE1 inhibition increased expression
of those markers in the aforementioned tissues (Figure 4.6 k and l). Ingenuity pathway
analyses on RNA sequencing data of BAT upon RO5508887 treatment not only confirmed
a global up-regulation of transcriptional networks associated with BAT differentiation,
but also revealed a down-regulation of skeletal muscle differentiation pathways (Figure
4.6 m).
These results support the idea that improvements in adiposity and glucose homeostasis
due to BACE1 inhibition are related to an increased BAT activity.
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4.7 Generation of stable Bace1 knock-out C2C12
myoblasts
Our in vitro and in vivo results on BACE1 modus operandi suggest, that BACE1 regulates
metabolism via tuning the switch between brown adipose tissue (activation) and skeletal
muscle (inhibition). We thus decided to generate stable Bace1 knock-out in C2C12
myoblasts to asses if Bace1 deletion - rather than a mere knock-down - has an even more
pronounced effect on the myogenic and adipogenic potential of these cells. Many Bace1
knock-out mouse models have been generated during the years using different targeting
strategies. The first BACE1 in vivo studies in 2001 used three main strategies: deletion
of a 2 kb section of Bace1 containing exon 1 [30], deletion of exon 4-8 that removes one
of the two aspartate residues at the protease’s active site [189] or deletion of exon 2
resulting in a shift of the open reading frame, hereby generating a STOP codon in exon 3
[32] (Figure 4.7 a). Considering that large genomic deletions can be problematic to obtain,
we estimated the latter strategy to be the most promising for a successful knock-out, due
to the small size of exon 2 (89 bp).
4.7.1 Generation of a knock-out cell line using CRISPR/Cas9
technology
The CRISPR/Cas9 system derives from the immune system of from Streptococcus pyo-
genes where it confers the bacteria the ability to recognise and degrade DNA from
invading viruses. The system was first re-engineered by the group of Prof. Emmanuelle
Charpentier by fusing the bacterial CRISPR RNA (crRNA) and trans-activating CRISPR
RNA (tracrRNA) into a single-guide RNA (gRNA), which then directs a Cas9 endonu-
clease to introduce site-specific double-strand breaks in target DNA [190]. Given the
simplicity and versatility of this system, many different methodologies and vector designs
were generated in recent years (reviewed in [191]). For our purpose we decided to use a
modified version of the pX330 CRISPR/Cas9 plasmid [174] containing two gRNAs and
carrying a GFP-puromycin selection cassette [175] (Figure 4.7 b). The two gRNAs were
designed to flank exon 2 of Bace1 and positively transfected cells were identified via GFP
and puromycin selection. C2C12 cells that survived puromycin selection were diluted to
a ratio of 1 cell/well in a 96-well plate to obtain monoclonal cultures.
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FIGURE 4.7. Generation of a stable Bace1 knock-out in C2C12 myoblasts.
a Genomic sequences diagram of Bace1. Bace1 exons are depicted as green boxes. Scissors
indicate targeted knock-out cleaving sites, STOP sign indicates stop codon generated
by frameshift due to exon 2 knock-out. b Schematic representation of modified pX330
CRISPR/Cas9 plasmid (Amp, ampicillin resistance cassette; CBh, chicken β-actin (CBA)
promoter; GFP, green fluorescent protein; PuroR, puromycin resistance cassette; U6, U6
promoter). c Schematic representation of PCR-based screening method indicating expected
DNA products (top). DNA products for PCR OUT and PCR IN (described above) detected
by gel electrophoresis (bottom). d DNA sequencing results of indicated DNA products
visualised in the UCSC Genome Browser (genome.ucsc.edu). e Relative expression of
indicated exon spanning Bace1 probes in C2C12∆Bace1 cells. Experiments were performed
in triplicate and represent the average of three independent experiments. f Immunoblot
analysis of BACE1 in C2C12∆Bace1 cells. Image is representative of two independent
experiments. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
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4.7.2 Validation of Bace1 knock-out
PCR analysis
For evaluation of correct Bace1 exon 2 deletion in selected C2C12 cell clones, we utilised
a PCR-based screening method (summarised in Figure 4.7 c). For this we performed PCR
analyses on DNA of putatively positive cells using two different sets of primers. The first
set (PCR OUT) amplifies DNA outside the gRNAs-targeted region, giving rise to a bigger
DNA product (609 bp) in case of unsuccessful Bace1 exon 2 deletion, and a smaller one
(364 bp) in case of effective exon 2 knock-out. Heterozygous cells would show both DNA
products. The second set (PCR IN) is internal to the gRNAs-targeted region and a band
of 159 bp would be detected on the agarose gel only for wild-type or heterozygous cell
clones. Figure 4.7 c shows the PCR results obtained for both PCR OUT and PCR IN in
40 C2C12 cell clones. Some samples presented no bands in neither PCR, probably due
to insufficient amounts of DNA obtained from these clones. One of the samples showed
only the knock-out band in the PCR OUT, but a product was still detected in the PCR
IN (18 in Figure 4.7 c). Surprisingly, all putatively heterozygous samples (31 is shown
as an example in Figure 4.7 c) showed an additional third band just below the expected
wild-type band. Only one cell clone (42) unequivocally showed the pattern expected from
a complete knock-out of Bace1 exon 2.
DNA sequencing analysis
PCR products from PCR OUT were extracted from the agarose gel and analysed by
DNA sequencing (2.10). The sequencing was performed on each sample showing a KO
band (Figure 4.7 c). In case of putative heterozygosity both wild-type bands were also
analysed. DNA sequencing of selected cell clones revealed one homozygous and one
heterozygous knock-out of Bace1 exon 2 (42 and 31 respectively in Figure 4.7 d). The two
distinct wild-type bands of the heterozygous samples were sequence-wise identical, but
showed micro-indels around gRNAs binding sites (data not shown). Since this region
is noncoding and contains no known noncoding RNAs or regulatory elements such as
gene enhancers/silencers, those indels should not affect proper transcription of the Bace1
gene. C2C12 cells obtained from clone 42 will be from now on named C2C12∆Bace1, while
heterozygous cells (clone 31) will be named C2C12∆Bace1/+.
Messenger RNA analysis
To further validate whether deletion of Bace1 exon 2 from one or two alleles was associ-
ated with a decrease in Bace1 mRNA levels, we performed qPCR analysis of C2C12∆Bace1
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and C2C12∆Bace1/+ cells. To asses if differential RNA splicing would occur upon exon
2 deletion, we used four different Bace1 TaqMan™ probes, each targeting a different
exon-exon junction (1-2, 3-4, 4-5, 8-9). Results confirmed a partial reduction of Bace1 ex-
pression levels in C2C12∆Bace1/+ cells in all tested probes (Figure 4.7 e). For C2C12∆Bace1
we could detect a 100% decrease in Bace1 mRNA only with the probe targeting exon
1 and 2, while residual splicing variants were detected for the remaining three probes
(Figure 4.7 e). However, due to our Bace1 targeting strategy (shown in Figure 4.7 a
and explained in 4.7) these splicing variants should not affect the decrease in BACE1,
especially considering that the mRNA levels detected for exon 3 (where the alternative
STOP codon arises) are comparable with the ones of the other exons.
Protein analysis
In order to validate whether deletion of exon 2 leads to an abrogated Bace1 transla-
tion despite the presence of alternative splicing isoforms we performed a western blot
analysis of C2C12∆Bace1 cells. The 70 kDa expected protein product present in C2C12
was undetectable in the knock-out cell line (Figure 4.7 f), giving final validation that
a complete knock-out of BACE1 occurred in C2C12∆Bace1. For further studies only the
homozygous C2C12∆Bace1 cell line was used.
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4.8 Bace1 knock-out in C2C12 blocks myogenesis
while promoting adipogenesis
4.8.1 Myogenesis is halted in Bace1-null cells
Having successfully generated a Bace1 knock-out model, we first determined the effect of
Bace1 deletion on C2C12 myogenesis. Already at confluence C2C12∆Bace1 cells revealed a
morphological phenotype, showing a distinctly rounder shape than the expected tapered
shape of wild-type myoblasts. Knock-out cells maintained this shape throughout the
entire myogenic differentiation protocol, while control C2C12 fused to form myocytes
(Figure 4.8 a). This phenotype was associated with a complete down-regulation of myo-
genic markers like Ckm, Myf6, Myog and Tnnt3 (Figure 4.8 b).
These data could confirm the anti-myogenic effect of Bace1 deletion not only on qPCR
but also on a morphological level.
4.8.2 Forced adipogenic differentiation of C2C12∆Bace1 cells
reveals increased adipogenic potential
As our Bace1 knock-down experiments in PIBA cells (4.4.2) hinted towards increased
adipogenesis and since confluent C2C12∆Bace1 cells resembled a round, adipocyte-like
phenotype, we decided to treat the myogenic C2C12∆Bace1 cell line with a pro-adipogenic
cocktail as described by Seale et al. [70]. Forced adipogenic differentiation of Bace1 knock-
out cells, but not wild-type controls, promoted lipid droplet formation and an adipocyte-
like mRNA expression profile for adipogenic markers like adiponectin (Adipoq), fatty-acid
binding protein 4 (Fabp4) and specific brown fat markers like cell death-inducing DNA
fragmentation factor, alpha subunit-like effector A (Cidea), Elovl3 and Ucp1 (Figure
4.8 c). Upon prolonged exposition to the adipogenic cocktail, C2C12∆Bace1 cells showed
an even higher amount of lipid-laden adipocyte-like cells (Figure 4.8 d). Interestingly,
only BAT-specific genes as Cidea, type II iodothyronine deiodinase (Dio2), Elovl3 and
Ucp1, but not pan-adipogenic genes, increased their expression compared to the shorter
adipogenic procedure (Figure 4.8 e). Both adipogenic differentiation treatments showed
a down-regulation of muscle markers like Myf5 and Pax3 in knock-out cells compared to
wild-type C2C12 (Figure 4.8 d and e).
We could hereby show that to the detriment of myogenic potential, C2C12∆Bace1 myoblasts
could be forced into a specifically brown adipogenic expression profile and morphology.
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FIGURE 4.8. Bace1 knock-out in C2C12 blocks myogenesis while promoting adipo-
genesis.
a Photomicrograph of C2C12 and C2C12∆Bace1 cells after myogenic differentiation. Image
is representative of three independent experiments. b Relative expression of indicated
genes in C2C12 and C2C12∆Bace1 cells after myogenic differentiation. c Relative expression
of indicated genes in C2C12 and C2C12∆Bace1 cells after adipogenic differentiation. d Pho-
tomicrograph of C2C12 and C2C12∆Bace1 cells after long adipogenic differentiation. Image
is representative of three independent experiments. e Relative expression of indicated
genes in C2C12 and C2C12∆Bace1 cells after long adipogenic differentiation. f Schematic
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representation of conditioned media experiment (details in 2.7.6.4). g Photomicrograph of
C2C12 and C2C12∆Bace1 cells after adipogenic differentiation in conditioned medium. Image
is representative of three independent experiments. h Relative expression of indicated genes
in C2C12 and C2C12∆Bace1 cells after adipogenic differentiation in conditioned medium. All
experiments were performed in triplicate and represent the average of three independent
experiments. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
4.8.3 C2C12∆Bace1 conditioned medium promotes adipogenic
differentiation of wild-type C2C12
As described in 1.2.2 the main enzymatic activity of BACE1 consists in the cleavage
of transmembrane proteins. We thus hypothesised that the pro-adipogenic phenotype
shown by C2C12∆Bace1 cells could occur due to the lack of peptides in the medium, which
physiologically would be cleaved by BACE1. Wild-type C2C12 cells were therefore given
conditioned medium from either knock-out or wild-type cells during the initial phase of
forced adipogenic differentiation (Figure 4.8 f, details in 2.7.6.4). To avoid a bias due to
potentially alternating nutrient consumption rates by donor cells, we supplemented the
conditioned medium with fresh nutrients prior to administration to wild-type C2C12.
Although cells in both treatment conditions showed a tapered shape, the ones exposed to
C2C12∆Bace1 conditioned medium presented widespread lipid droplet formation (Figure
4.8 g). This phenotype was supported by an increased expression of adipose tissue-specific
genes like Adipoq, Fabp4, Pparg, Cidea and peroxisome proliferative activated receptor,
gamma, coactivator 1 alpha (Ppargc1a) (Figure 4.8 h).
Taken together, our results show that the C2C12∆Bace1 secretome lacks un-identified
BACE1-cleaved peptides, allowing the secretome to support (brown) adipogenesis.
75
CHAPTER 4. RESULTS
4.9 Proteomic analysis of C2C12∆Bace1 reveals
potential BACE1 targets
We could show that the BACE1 sheddome in C2C12, consisting in the totality of protein
peptides cleaved by the sheddase BACE1, affects the adipogenic potential of the myogenic
cell line (4.8.3). We hence approached identification of proteins targeted by BACE1
enzymatic activity, which could account for this phenotype.
Since the discovery of the therapeutical potential of BACE1 inhibition in counteracting
AD, many efforts have been undertaken to discover BACE1 targets aside APP in order
to evaluate potential side effects of a BACE1-based therapy. While most studies on
BACE1 target identification focussed on the nervous system [192][180] and few others
on selected peripheral tissues [193][194], no studies have been performed on BACE1
cleaving targets in muscle or adipose tissue. To identify BACE1-cleaved peptides in
these latter tissues, we utilised our C2C12∆Bace1 model for a complementary proteomic
approach: first ascertain enriched proteins on the cell surface of Bace1 knock-out cells
and then determine the lack of cleaved peptides in the medium of the same cell line.
4.9.1 Bace1 knock-out exhibits accumulation of cell surface
proteins from the PI3K/AKT-FGFR-EGFR signalling
pathway
For the identification of cell surface proteins potentially targeted by BACE1, we used the
cell surface capturing (CSC) technology [196]. This technology exploits the fact that most
cell surface proteins are predicted to be glycosylated and covalently labels a chemical tag
to these extracellular glycan moieties on living cells (Figure 4.9 a).
Relative quantitative comparison of the detected cell surface glycoproteins of C2C12∆Bace1
and wild-type C2C12 revealed 79 differentially expressed proteins (Figure 4.9 b). Since
the lack of BACE1 from C2C12 cells could allow detection of surface proteins otherwise
cleaved by the β-scretase in wild-type cells, we focussed exclusively on the significantly
up-regulated proteins in knock-out cells (45). The protein with the highest positive fold
change was the pro-inflammatory amine oxidase, copper containing 3 (AOC3). However,
over-representation and protein enrichment analysis performed on the up-regulated
proteins using a publicly available online tool (consensuspathdb.org) depicted among the
most affected the PI3K/AKT, FGFR and EGFR signalling pathway, including proteins
like epidermal growth factor receptor (EGFR), beta-type platelet-derived growth factor
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FIGURE 4.9. Proteomic analysis of C2C12∆Bace1 reveals potential BACE1 targets.
a Schematic representation of CSC method (adapted from [195]). b Volcano plot of C2C12
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versus C2C12∆Bace1 CSC results. Significant differentially expressed protein are represented in
green. c Immunoblot analysis of indicated proteins in C2C12 and C2C12∆Bace1 cells. Image
is representative of two (EGFR) or three (PDGFRβ) independent experiments. d Schematic
representation of iSPECS method (adapted from [180]). e Volcano plot of C2C12 versus
C2C12∆Bace1 iSPECS results. Significant differentially expressed protein are represented
in green. f Bubble plot of results merged from differentially expressed proteins in CSC and
iSPECS. Significance of CSC results is indicated by colour and significance of iSPECS results is
indicated by size. g Relative expression of indicated genes in C2C12 and C2C12∆Bace1 cells. h
Immunoblot analysis of AOC3 in C2C12 and C2C12∆Bace1 cells. Image is representative of three
independent experiments. HMW, high molecular weight; LMW, low molecular weight.
receptor (PDGFRβ), kit ligand (KITLG) and members of the FGFR family (fibroblast
growth factor receptors). The whole list of CSC-detected proteins in this pathway are
listed in Table 6.1 (Appendix). Western blot validation of EGFR and PDGFRβ confirmed
an up-regulation of these membrane proteins in C2C12∆Bace1 cells (Figure 4.9 c).
4.9.2 Conditioned medium proteomic analysis reveals known
and putative BACE1 targets
Having identified various proteins enriched on the cell surface of Bace1 knock-out cells,
we hypothesized that as true targets of BACE1 cleaving, peptides of those proteins should
in turn be less detected in the cell supernatant.
Investigation of the sheddome of BACE1 via mass-spectrometry of cell medium encoun-
ters three main limitations [197]. First, secreted proteins can have very low concen-
trations in the media. Second, physiological media include supplements such as fetal
calf serum containing albumin and other serum proteins at concentrations that could
interfere with the mass-spec analysis. Third, secretome proteins can be masked by highly
abundant cytosolic proteins released from broken or apoptotic cells. To circumvent these
limitations and allow proteome-wide identification of shedding substrates and secreted
proteins, we utilised the secretome protein enrichment with click sugars (SPECS) tech-
nique for the study of C2C12∆Bace1 secretome (Figure 4.9 d). This technique was first
developed by the laboratory of Prof. Stefan Lichtenthaler [180] and further improved
[181]. For our study we utilised a further improved SPECS method (iSPECS) in collabo-
ration with Prof. Stefan Lichtenthaler.
Results showed a total of 272 peptides at differential concentrations among the two
analysed media (Figure 4.9 e), of which 155 were down-regulated upon knock-out of
Bace1 in C2C12. Some of these potential BACE1 substrates have also been found in
other BACE1 sheddome analyses, such as members of the semaphorine family SEMA4C
and SEMA6A [192].
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4.9.3 AOC3 is a potential target of BACE1 and could trigger
endocrine regulation of metabolism
To integrate our two proteomic approaches we selected significantly regulated peptides
of both CSC and iSPECS analysis (Figure 4.9 f). Among proteins up-regulated on the
surface of C2C12∆Bace1 cells and down-regulated in the medium of the same cell line,
we found AOC3, an amine oxidase with proinflammatory functions [198][199]. Interest-
ingly, AOC3 (also known as VAP-1) exhibits a soluble form (soluble AOC3 or sVAP1)
cleaved by metalloproteases [200], which can be found in serum, where concentrations
are augmented in AD [201][202], diabetes and obesity [203][204]. Moreover, both the
membrane-bound and soluble form of AOC3 have been reported to be expressed in
murine and human adipocytes [200].
Notably, both AOC3 peptide sequences detected by iSPECS are shared by AOC3 and its
homologous amine oxidase, copper containing 2 (AOC2), while another detected sequence
was unique for AOC2. Unfortunately, due to the automatised procedure utilised for the
standardisation, it was not possible to obtain standardised results for the single pep-
tides. We therefore analysed the mRNA expression of the two amine oxidases in our cell
model. While Aoc2 expression was unaltered, Aoc3 mRNA was surprisingly increased in
C2C12∆Bace1 cells (Figure 4.9 g), even correlating with an increase of the high molecular
weight isoform of AOC3 protein (HMW in Figure 4.9 h). However, smaller isoforms of
the protein, potentially cleaved by BACE1, were - in accordance with the iSPECS results
- decreased in C2C12∆Bace1 (LMW in Figure 4.9 h)
In conclusion we could show that throughput proteomic analysis of Bace1 depleted
surfaceome and medium identified AOC3 as putative novel target of the protease in
peripheral tissues, with the potential of pursuing an endocrine regulation of metabolism
and - perhaps - Alzheimer’s disease.
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DISCUSSION
Obesity has become a major burden in modern society, with nowadays more than twiceas many people affected as in 1980 [1]. The increased fat deposition and impaired
glucose metabolism associated with obesity lead to a greater risk for co-morbidities, such
as type 2 diabetes and dementia, in particular Alzheimer’s disease [3] [4] [5].
To counteract the obesity pandemic and its sequelae, brown adipose tissue activation
has been proposed as promising therapeutic target. Thanks to its thermogenic activity
due to high enrichment of UCP1, BAT can significantly increase energy expenditure
with beneficial effects on whole body metabolism. Despite previously considered to be
present only in rodents and human newborns, this tissue has been recently detected
as functional in adult humans as well. Similar thermogenic activity was also found in
adipocytes within WAT, which were henceforth defined as beige or brite. Beige adipocytes
are mainly located within murine subcutaneous and human visceral fat depots [205],
which both arise from a white adipogenic lineage, contrarily to BAT which shares a
precursor lineage with SM.
The activation of thermogenic potential has been shown to be also dependent on various
noncoding RNAs, with lncRNAs [206] and especially miRNAs [154] being able to regulate
brown adipogenesis, browning of white adipocytes and transdifferentiation between
myocytes and brown adipocytes.
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5.1 MiR-328 regulation of BAT partially determines
Dicer1 knock-out in vivo phenotype
MicroRNAs are short noncoding RNAs able to block gene expression via targeting
sequence-specific mRNAs. MiRNAs are generated in the nucleus and undergo two cleav-
ing steps and exportation to the cytoplasm. DICER1 is one of the two ribonucleases III
involved in miRNA biogenesis and is responsible for the final cleavage that leads to
mature miRNA generation (1.5).
Control of miRNA expression by DICER1 was shown to have an important role in the reg-
ulation of AT homeostasis, with results from our group and others [151] indicating that a
deficiency of Dicer1 in pan- (AdicerKO mice) or brown adipose tissue (Dicer1∆BAT/+) leads
to a deteriorated glucose metabolism. AdicerKO mice exposed to HFD exhibit abnormal
fat accumulation with an overall decrease in body weight and reduced WAT mass, while
BAT mass is increased due to whitening of this tissue [151]. Our Dicer1∆BAT/+ mouse
model on the other hand shows no difference in body weight and a mere female-confined
increase in fat mass [170]. These differences can be explained by discrepancies in the
tissue distribution of Dicer1 deficiency between the two mouse models: AdicerKO mice
express Cre recombinase under control of the more abundant Adiponectin promotor
which leads to a decrease in Dicer1 expression by 60-80% in all adipose depots (SCAT,
VAT, BAT) [151]. Au contraire Dicer1∆BAT/+ mice express Cre recombinase under control
of the BAT-specific Ucp1 promotor, generating a 25% decrease in the ribonuclease expres-
sion exclusively in BAT. Notably, this mouse model exhibits a concomitant increase in
Dicer1 expression in WAT, possibly due to compensatory mechanisms [170]. Despite these
differences, both mouse lines manifest a defective glucose homeostasis, suggesting that
glucose intolerance and insulin desensitisation in these mice is dependent on the effects
of Dicer1 down-regulation specifically in BAT. The impairment of glucose metabolism
observed in Dicer1∆BAT/+ mice however, did not alter the blood levels of neither insulin
nor leptin and was also not associated with any kind of adipose tissue redistribution
(4.1.1), which is a characteristic of AdicerKO mice [151]. Moreover, Dicer1∆BAT/+ mice
exhibited no differences in BAT mass compared to controls, in line with observations
made by Mudhasani et al. in aP2-Cre Dicer1 knock-out mice [149].
To determine whether the Dicer1 knock-out phenotype may be attributed to specific
miRNAs, those miRNAs enriched in BAT with a correlation to BAT activity, were investi-
gated for their potential in regulating brown adipocyte differentiation and function. In
vitro loss- and gain-of-function studies revealed that the AT-enriched (4.2.1) miR-328,
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could promote adipogenesis of brown adipocytes while inhibiting the myogenic potential
of both myoblasts and PIBAs (4.2.2). Since Dicer1∆BAT/+ mice show decreased expression
of miR-328 (4.2.1), the defective brown adipogenesis upon miR-328 knock-down could
explain the reduced UCP1 expression observed in this mouse line (4.1.1). Moreover, as
miR-328 does not alter differentiation and adipogenic marker expression in the white
adipocytes 3T3-L1, the effects of the miRNA seem to be brown lineage-specific (4.2.4).
This BAT-specificity was also confirmed by experiments investigating brown adipocyte
activity: Indeed, miR-328 over-expression was proven to increase maximal respiratory
capacity of PIBA cells (4.2.3), which could attribute to the decreased EE observed in
Dicer1∆BAT/+ mice [170].
However, miR-328 alone is not likely to explain the entire metabolic phenotype observed
in Dicer1∆BAT/+ mice considering the wide regulatory network of miRNAs, with these
noncoding RNAs being able to regulate multiple gene targets and single genes being
inhibited by multiple miRNAs [135]. Among the miRNAs that could have an additive
effect on the Dicer1∆BAT/+ phenotype, there are miR-193b, included as a positive control
in our in vitro experiments (3, 4.2), and miR-365. These belong to the same miRNA
cluster and were shown in vitro to regulate brown adipogenesis and myogenesis [168].
Analysis of their expression in our Dicer1 knock-out model showed a defect in maturation
of miR-193b and miR-365 in the BAT of Dicer1∆BAT/+ mice (4.2.1). MiR-365 was also
shown by Mori and colleagues to increase levels of Ucp1 mRNA by 20-fold in AdicerKO
pre-adipocytes, reversing the effects of Dicer1 knock-out [151].
Taken together, miR-328 is part of a miRNA regulatory network, possibly including
the miR-193b-miR-365-cluster, involved in the regulation of brown adipocyte differen-
tiation and activity, and obesity-related defects in this network function can lead to a
deterioration of energy and glucose homeostasis.
5.2 In vitro Bace1 inhibition resembles the
miR-328-dependent pro-brown-adipogenic
phenotype
Although miR-328 is conserved in humans, its therapeutic use could imply complications
due to three main reasons. First, given the broad spectrum of targets that a single miRNA
can regulate, more information on the potential miR-328 gene targets are needed. Second,
given the positively correlated effects of miR-328 on BAT function, an over-expression
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approach would be needed for an enhancement in BAT activity. However, to date in
the field of miRNA therapeutics, inhibition of miRNAs is the predominant approach in
human studies, while an over-expression approach was limited to only one single study
[207]. Third, selective and effective delivery of miRNAs into BAT are difficult to achieve
with state of the art techniques and potential side effects of miR-328 over-expression
in other tissues would have to be determined. For these reasons, we set our focus onto
the identification of targets of miR-328 which may play an important role in peripheral
metabolism via regulating BAT and SM activity.
Considering the inhibitory activity of miRNAs in regulating gene transcription, our find-
ings of miR-328 function in BAT suggest that the downstream gene targets of miR-328,
instead of eliciting a pro-adipogenic phenotype, could in turn rather be related to SM
homeostasis as seen - in a reverse way - with miR-133 inhibition of Prdm16 [166]. Our
hypothesis is in line with the bidirectional regulation between BAT and SM due to their
shared progenitor cells [208]. Gene candidates were selected based on their proposed role
as myogenic regulators. In particular, we focused on those genes harbouring a potential
miRNA binding site for both miR-328 and miR-193b. Fulfilling these selection criteria
the β-site amyloid precursor protein cleaving enzyme 1 (Bace1) was revealed as directly
regulated by the two miRNAs (4.3.1-2). Interestingly, and in line with our hypothesis,
Bace1 knock-down was proven to regulate myogenesis and brown adipogenesis in a way
that evoked miR-328 action:
In C2C12 myoblasts reduced expression of Bace1 or miR-328, inhibited or promoted
differentiation, respectively. Furthermore, while the miRNA generally altered myogenic
markers, the β-secretase affected exclusively late myogenic markers (4.4.1). This discrep-
ancy could occur due to the inhibition by miR-328 of various targets involved in muscle
regulation, leading to additional early defects in myogenesis. For example, miR-328
over-expression in the heart was shown to induce cardiac hypertrophy by targeting
SERCA2a [209]. Another example is the proto-oncoprotein proviral integration site 1
(PIM-1), which in addition to its crucial role in tumorigenesis has also been implicated
in vascular diseases and smooth muscle cell proliferation [210] [211]. Indeed, miR-328-
mediated inhibition of Pim-1 was shown to significantly reduce muscle cell proliferation
through a mechanism involving the platelet-derived growth factor PDGFBB [212]. These
results expand the knowledge on myogenic regulation by BACE1, whose function in
this context was previously focused to its role, together with Neuregulin-1 (NRG1), in
maintaining motor coordination through regulation of muscle spindle physiology [33].
Regarding brown adipogenesis, the exactly opposing effects of Bace1 and miR-328 as
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its inhibitor appear more consistent. The inhibition of Bace1 in PIBAs promoted brown
adipocyte differentiation and lipid accumulation, which was associated with increased
Ucp1 expression (4.4.2), revealing in an opposite manner the effects observed upon
miR-328 knock-down in the same cell line (4.2.3). Moreover, both Bace1 down-regulation
and miR-328 over-expression increased the maximal respiratory capacity of PIBA cells
(4.4.2, 4.2.3), supporting a role for the miR-328-Bace1 axis in enhancing BAT activity.
Although miR-328 has so far not been attributed any function in BAT - or even in any
AT in general - BACE1 was recently suggested to play a role in brown fat homeostasis,
with Bace1 knock-out mice showing an increased expression of UCP1 in BAT [34].
Collectively, our results unveiled a novel miR-328-Bace1 nexus that is able to prompt
BAT activity in vitro via regulating both myogenesis and brown adipogenesis.
5.3 In vivo inhibition of BACE1 counteracts
obesity-associated deterioration of glucose
metabolism
Bace1 knock-out mice have been extensively studied since the discovery of BACE1 as the
β-secretase involved in amyloid plaque formation in AD. However, only in recent years
and in sparse studies this mouse model has been investigated from a metabolic point of
view. Meakin and colleagues could show that mice lacking Bace1 display decreased adipos-
ity, higher energy expenditure and improved glucose and peripheral insulin metabolism
compared to controls at 8-12 months of age [34]. These effects were observed upon both
NCD and HFD feeding. Nevertheless, further studies utilising younger Bace1-/- mice
could not reproduce the effects on glucose tolerance and insulin sensitivity, yet con-
firming the decrease in body weight and plasma insulin concentrations [213]. However,
the Bace1-/- mouse model has been shown to manifest various side effects due to the
numerous physiological substrates of BACE1 [17]. Our approach exploited the thera-
peutic potential of BACE1 in the context of obesity employing an inhibitor of BACE1
(RO5508887) which was toxicologically tested in mice for AD-related uses [43]. This
approach was also based on our finding that BACE1 is over-expressed in BAT of obese
mice (4.5), while previous reports showed no differences in its expression in the brain of
HFD-fed mice [214]. By feeding RO5508887 mixed in the HFD to wild-type mice already
exposed to diet-induced obesity for three weeks, we could assess beneficial effects of the
inhibitor on obesity-dependent metabolic decline. In line with observations in the Bace1
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knock-out mouse model, BACE1 inhibition led to a decrease in weight gain in already
obese mice (4.6.1). These findings, together with our results on Bace1 inhibition in PIBAs,
hint to a role for the β-secretase in the obesity-dependent deterioration of BAT function
(1.3.1.2).
BACE1 was shown to regulate glucose metabolism in muscle cells, with BACE1 inhi-
bition in C2C12 cells leading to increased glucose uptake and oxidation, GLUT4 cell
surface translocation and basal rate of oxygen consumption [35], whereas increased
neuronal BACE1 was shown to be sufficient to impair systemic glucose metabolism [215].
In line with these and Bace1-/- [34] findings, BACE1 inhibition in our obese mouse model
also enhanced glucose tolerance and insulin sensitivity (4.6.2), pinpointing BACE1 as a
suitable target to counteract obesity-related impairment in glucose homeostasis. Our
mice also showed unaltered insulin secretion upon BACE1 inhibition (4.6.2), in line
with findings in Bace1 knock-out mice [213] and in contrast to observations in Bace2
whole body knock-out mice [188]. Although both BACE1 inhibition and Bace1 global
knock-out resulted in lower lean body mass, the protein inhibition in our mouse model
led to decreased VAT mass and visceral adipocyte size (4.6.3), while Bace1-/- mice exhibit
significantly increased VAT and SCAT depots [213].
The improved metabolism of BACE1-inhibited mice was associated with increased expres-
sion of brown fat-specific markers in both BAT and SCAT (4.6.4), indicating thermogenic
activation as a possible mechanism to explain the enhanced glucose homeostasis. Notably,
as suggested by our in vitro findings on adipogenic and myogenic regulation through
BACE1, transcriptional networks associated with BAT differentiation were up-regulated
in RO5508887-treated mice, while SM differentiation pathways were down-regulated
(4.6.4).
These results point out that BACE1 inhibition in vivo protects from diet-induced obesity
and impairment in glucose metabolism via activating thermogenesis in brown and white
adipose tissue.
5.4 BACE1 sheddome regulates the switch between
myogenesis and brown adipogenesis
It is known that some highly potent transcription factors such as PPARγ, C/EBPα [99]
or more recently PRDM16 [70] are able to promote brown adipogenesis in SM due to the
shared cell lineage of the two tissues. Since BACE1 inhibition was shown to promote
brown adipogenesis to the detriment of myogenesis both in vitro and in vivo, our interest
85
CHAPTER 5. DISCUSSION
focused on the potential ability of Bace1 to stimulate a transdifferentiation process in
myocytes/brown adipocytes, rather than focusing on single cell lineages. Bace1 inhibi-
tion in C2C12 was already investigated by us and others [35] for its role in inhibiting
myogenesis and promoting glucose uptake, but no studies have been performed so far
on a Bace1 potential to stimulate brown adipogenesis in this myogenic line. Complete
knock-out of the β-secretase was therefore obtained in the C2C12 cell line (C2C12∆Bace1)
(4.7). This in vitro model was stronger than a mere inhibition of Bace1 mRNA and could
also be used for further proteomics analysis as it will be described in the next chapter
(5.4).
BACE1 is known to have a role in muscle homeostasis in vivo with knock-out mice
showing defects in the formation, maturation and maintenance of muscle spindles [33].
In line with these results, C2C12∆Bace1 cells showed a block in myogenesis with an
almost complete down-regulation of myogenic genes (4.8.1). Strikingly, the knock-out
of Bace1 affected the morphology of C2C12, which presented a round, adipocyte-like
shape at confluence, showing a much stronger pro-adipogenic effect upon depletion of
the β-secretase compared to our results using LNA inhibitors (4.4.1.
To investigate the adipogenic potential of C2C12∆Bace1 cells, the cell line underwent a
pro-adipogenic stimulation which was previously shown to promote an adipocyte-like
phenotype in myocytes [70]. Forced adipogenic stimulation revealed that the changes
in morphology of C2C12∆Bace1 cells were associated with an increase in lipid droplet
accumulation and up-regulation of both WAT- and BAT-related genes (4.8.2). Further-
more, prolonged adipogenic stimulation of C2C12∆Bace1 cells increased the expression of
brown adipocyte-specific genes even further, while the up-regulation of pan-adipogenic
markers remained unchanged (4.4.2). These results suggest that Bace1-dependent regu-
lation of myogenic and adipogenic transdifferentiation promotes specifically the brown
lineage. For this purpose, experiments specifically targeting the thermogenic activity
of C2C12∆Bace1 cells would be required. However, further investigations are needed in
this direction since it is not possible to unequivocally exclude a more general adipogenic
role for Bace1. Having identified BACE1 as in vitro transdifferentiation effector between
brown adipocytes and myocytes, it is worthy investigating, whether BACE1 may interact
with other known proteins regulating cell fate decision of these two cell lines. Indeed
Pparg, shown to be increased in C2C12∆Bace1 cells, has been proposed as a repressor of
Bace1, whose gene promoter contains a binding site for this transcription factor [216].
The up-regulation of Pparg upon Bace1 knock-down could therefore establish a negative
feedback loop leading to further repression of BACE1 and resulting in a subsequently
86
CHAPTER 5. DISCUSSION
more pronounced adipocyte-like phenotype. However, whether this feedback loop holds
true also for myocyte and brown adipocyte regulation remains to be elucidated.
With BACE1 being a protease of the sheddase family, its function is based on its cleaving
activity on specific substrates. Although BACE1 cleavage of APP in the nervous system
is the best characterised example of this sheddase’s proteolytic function, different ad-
ditional substrates have been discovered in the last years for BACE1 outside the brain
[217]. Shedding by BACE1 in peripheral tissues could therefore generate a series of
peptides able to activate brown adipogenesis through paracrine and endocrine regulation
of tissues like SM, BAT end WAT. These peptides could be produced by BAT, which is
a known endocrine tissue with different hormones, such as FGF21, shown to regulate
thermogenesis and browning via peripheral and central signalling [65].
To investigate whether knock-out of Bace1 affects the pool of peptides released by the
cells and whether these in turn are responsible for the pro-adipogenic phenotype ob-
served in C2C12∆Bace1 cells, conditioned medium from C2C12∆Bace1 and control cells
was given to wild-type C2C12, which then underwent forced adipogenic differentiation.
The BACE1-depleted conditioned medium was able to enhance the adipogenic potential
of C2C12 myoblasts, as revealed by increased lipid accumulation and up-regulation of
adipose tissue-specific genes (4.8.3), including Pparg which, as aforementioned, was able
to promote adipogenesis in SM. The effect of C2C12∆Bace1 conditioned medium hint to a
potential role that BACE1 substrates could have in regulating BAT/SM shared cell fate.
These results inquire about whether similar approaches could be valid in different in
vitro models, such as various combinations of co-cultures. Further investigations are
needed to study how BACE1-depleted medium from myocytes could regulate brown or
white adipocytes or even neuronal populations.
5.5 Potential BACE1 substrates involved in
peripheral metabolism regulation
Since the function of a protease is defined by its substrates, the identification and char-
acterisation of novel BACE1 targets involved in adipogenic and myogenic homeostasis is
fundamental to investigate their potential role in the regulation of metabolism. Although
various substrates of the β-secretase have been identified, none of them were verified in
adipocytes or myocytes. In light of our conditioned medium results, proteomic analysis
were performed in our C2C12∆Bace1 model and compared to wild-type cells. Our approach
involved two distinct but complementary methods: cell surface capturing (CSC), which is
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able to quantify proteins present specifically on the cell surface, and iSPECS, an improved
proteomic analysis of conditioned media peptide contents (4.9). The latter is a state of the
art technique which - in contrast to previous proteomic approaches [192] - is able to detect
very small amount of cleaved or released proteins while avoiding interference with serum
and cytosolic proteins and false positive substrate identification [181]. Both proteomic
approaches showed various protein peptides significantly altered in C2C12∆Bace1 cells
(4.9), some of which could be directly targeted by BACE1 and could play a role in the var-
ious in vitro and in vivo phenotypes dependent on the β-secretase discussed in this thesis.
EGFR and PDGFRβ
CSC analysis of Bace1 knock-out myoblasts revealed a total of 79 differentially expressed
proteins, of which 45 were up-regulated on the surface of C2C12∆Bace1 cells compared to
C2C12 wild-type (4.9.1). Our focus on up-regulated proteins was based on the in vitro
model used: depletion of Bace1 in C2C12 should lead to lack of protein expression in
the cell surface, decreasing substrate cleavage and retaining full-length proteins on the
cell surface. To depict whether the proteins showed to be up-regulated by CSC belong to
specific interaction networks, an online tool (consensuspathdb.org) was utilised which
integrates data from 32 public resources for interactions and interactions curated from
literature. Over-representation and protein enrichment analysis performed on the 45
up-regulated proteins depicted among the most affected the PI3K/AKT, FGFR and EGFR
signalling pathway (Table 6.1, Appendix). The PI3K/AKT pathway was shown to be
activated during VAT expansion and to regulate proliferation in VAT but not in SCAT
[218]. Moreover, this pathway is a known interplayer in metabolic signalling control
[219]. Both FGFR and EGFR singalling pathways have been involved in the regulation
of metabolism [220] [221], with the latter playing a role in the neurometabolic signalling
regulating obesity, T2D, AD, cancer and cardiorespiratory function [220]. Among the
CSC-detected proteins up-regulated on the surface of C2C12∆Bace1 cells and involved in
this pathways, PDGFRβ and EGFR were validated as over-expressed in our cell model
via WB analysis (4.9.1).
PDGFRβ is a receptor member of the PDGF family, whose downstream pathways regu-
late multiple cellular functions such as proliferation, migration and immediate early gene
induction [222] and known to control vascular smooth muscle cell development [223].
Although little is known on whether PDGFRβ plays a role in adipocyte-myofibroblast
transition, the other receptor of the PDGF family, PDGFRα, was identified in human
and rodent SM as a marker of bipotent progenitors able to undergo differentiation into
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adipocytes and myoblasts [224]. Furthermore, PDGFRβ up-regulation on C2C12∆Bace1
cell surface could be a sign of the defective myogenic differentiation of C2C12: Indeed this
receptor stimulates angiogenesis, but its expression is down-regulated as soon as vascular
smooth muscle cells mature [225]. Moreover, PDGFRβ signalling in pre-adipocytes was
shown to have an inhibitory effect on white adipocytes, with reduced lipids and increased
undifferentiated cells, without altering brown adipogenesis [226]. This emphasizes a po-
tential role for PDGFRβ in regulating both myogenic and adipogenic differentiation, with
a differential regulation of white and brown adipocytes. However, subsequent iSPECS
analysis of C2C12∆Bace1 conditioned medium did not detect any peptide of PDGFRβ,
making this candidate not suitable as potential BACE1 target (4.9.2).
EGFR, also known as ErbB1, is a transmembrane receptor for members of the epidermal
growth factor (EGF) family of extracellular protein ligands, which was discovered many
decades ago [227]. Since then, this tyrosine kinase has been thoroughly studied and has
been shown to influence many cellular processes, especially tumour progression, but also
wound healing and the maintenance of organ and cellular homeostasis, in particular in
the cardiovascular system [228]. EGFR can be activated either directly by binding of EGF
or EGF-like ligands, or it can be trans-activated by shedding of EGFR-ligands by a disin-
tegrin and metalloproteases (ADAMs) or matrix metalloproteases (MMPs) [228]. The
role for EGFR in adipose tissue is unclear, with contradictory studies showing an effect
of EGFR in blocking maturation of adipocyte precursor cells into mature adipocytes [229]
or in enhancing adipogenesis in differentiated adipocytes [230]. Although the expression
of EGFR was increased on the surface of C2C12∆Bace1 cells, as validated also by WB
(4.9.1), a similar up-regulation was seen for the cleaved peptide in the cells’ conditioned
medium (4.9.2). This excludes the depletion of BACE1 as a regulator of EGFR cleavage
and activity, marking this protein, as well as PDGFRβ, a not suitable candidate for
BACE1-dependent peripheral metabolism regulation.
The sempahorines SEMA6A and SEMA4C
The two proteomic approaches utilised for this study, in particular iSPECS, revealed
among the protein significantly altered in C2C12∆Bace1 cells some previously proposed
as BACE1 substrates. Of particular interest was the semaphorine family, some members
of which were suggested in recent years to be cleaved by the β-secretase [192] [180]
[181]. Semaphorines are a family of proteins that regulates key cellular functions, such
as cell-cell interaction and communication, but also cell differentiation, morphology
and function, mainly via interaction with the plexin transmembrane receptors [231].
89
CHAPTER 5. DISCUSSION
Semaphorines are divided into 5 classes, all presenting a sema domain, yet harbouring
different functions and ways of action. Class 3 semaphorines are soluble, classes 4-6 are
transmembrane and SEMA7A is a GPI-anchored protein [231]. In our study iSPECS
analysis revealed peptides from SEMA6A and SEMA4C to be the first and fourth most
down-regulated ones respectively in the medium of C2C12∆Bace1 cells (4.9.2).
SEMA6A deficiency in rodents was associated with various axonal guidance and neuronal
migration defects [232] [233] and it was also shown to promote angiogenesis through reg-
ulation of endothelial cell survival and VEGF signalling [234]. In the context of adipose
tissue, SEMA6A was proposed to regulate innervation of BAT through a mechanism
involving expression of PlexinA4 - of the plexin family - in BAT-associated macrophages
[235].
Of greater interest for our study was SEMA4C, a class 4 semaphorine that can be pro-
teolytically cleaved to generate a soluble form [231]. Beyond its role in nervous system
and angiogenesis regulation shared with other semaphorines, SEMA4C was shown to
be important during myogenic differentiation [236] [237]. Using C2C12 and an in vivo
model for muscle regeneration, Ko and colleagues could show an up-regulation of the
semaphorine during in vitro differentiation and in vivo SM regeneration [236]. Moreover,
RNAi depletion of Sema4c in C2C12 resulted in the inhibition of myotube formation
and decreased expression of myogenic markers [236]. Further studies, testing both gain-
and loss-of-function of Sema4c in C2C12, supported the previous findings and proposed
the p38 MAPK pathway as responsible for SEMA4C enhancement of terminal myogenic
differentiation [237]. Interestingly Sema4c was also found to be over-expressed in the
brain of AD patients [238].
Although both semaphorines, but especially SEMA4C, could be interesting candidates for
BACE1-dependent regulation of myocytes/adipocytes transition, CSC analysis showed
the two proteins as being down-regulated also on the surface of C2C12∆Bace1 cells (4.9.1).
The decreased expression of SEMA4C and SEMA6A in both the surface and the condi-
tioned medium of Bace1 knock-out C2C12 could nonetheless be interpreted taking in con-
sideration the intracellular activity of BACE1. Indeed, considering that the β-secretase
activity is optimal in acidic environments, BACE1 is also present within the cell in
endosomes and the trans-Golgi network [17]. Thus, the results of CSC and iSPECS anal-
ysis could be explained by intracellular cleavage of SEMA4C and SEMA6A by BACE1.
However, further investigations including WB validation of the two semaphorines and
cellular localisation analysis are needed to test this hypothesis.
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The amine oxidase AOC3
The most promising candidate resulting from our proteomic analysis is certainly AOC3,
which was shown to be highly up-regulated on the surface of C2C12∆Bace1 cells, while
being down-regulated in the same cells’ conditioned medium (4.9.1-2). Other than for
its role as a semicarbazide-sensitive amine oxidase (SSAO), AOC3 has been shown
to regulate many cellular processes and has been proposed as therapeutic target for
various diseases, including inflammatory diseases, T2D, atherosclerosis, neurodegen-
erative diseases, obesity, hypertension and cancer [239]. Its pro-inflammatory activity
was demonstrated in liver where it promotes leukocyte recruitment and migration [199].
AOC3 was also shown to regulate glucose metabolism and a positive correlation was
found between serum AOC3 levels and BMI and body weight in T2D patients [203].
Involvement in glucose regulation was demonstrated in the adipose tissue of rats, where
AOC3 activity highly stimulated glucose transport via recruitment of GLUT4 to the
plasma membrane of adipocytes [240]. Moreover, increased glucose transport was also
found in GLUT4 vesicles from adipocytes and rat SM [240] and in human adipocytes
[241]. Most of AOC3 functions throughout the body are carried out by its soluble form
sAOC3, also known as sVAP1, which can be released into the bloodstream [239]. The
main source of sAOC3 seem to be adipocytes or vascular endothelial cells [239]. The
expression of this soluble form was also associated with AD, with sAOC3 being increased
in the plasma of AD patients [201] [202]. Soluble AOC3 is generated via cleaving of the
transmembrane full protein in a process that involves ADAM metalloproteases [200].
Indeed, Abella and colleagues could show decreased secretion of sAOC3 upon utilisation
of batimastat, a matrix metalloprotease inhibitor. Interestingly, batimastat is also an
inhibitor of BACE1 and was shown to reduce BACE1-dependent cleavage of APP [35].
These findings support the idea that the β-secretase could regulate the release of sAOC3
in BAT and SM, as also suggested by our results showing an increase in low molecular
isoforms of AOC3 - possibly sAOC3 - in C2C12∆Bace1 cells, despite increased expression
of both protein and mRNA of the full length AOC3 (4.9.3). However further studies are
needed to validate our hypothesis, in particularly regarding the possibility for BACE1 to
cleave the amino oxidase. The terminal amine isotopic labelling of substrates (TAILS)
technique could be utilised to determine the putative cleavage site for BACE1 [242].
Therefore, AOC3 could regulate inflammation and glucose metabolism via BACE1-
dependent release of its soluble form in the blood. Moreover, considering that chronic
inflammation, impairment in glucose homeostasis and energy metabolism are conditions
associated with obesity, T2D and AD [22], a paracrine or endocrine role for AOC3 in the
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regulation of these diseases cannot be excluded.
5.6 Perspectives
in vitro and in vivo inhibition of BACE1 showed beneficial effects on obesity-related
deterioration of glucose and energy homeostasis, possibly due to enhanced differentiation
and activation of BAT to the detriment of myogenesis. However, our in vivo results rely
on a global effect of the protease, not allowing insights into specific tissue regulation.
To investigate the in vivo relevance of the β-secretase in the regulation of BAT and SM
homeostasis, conditional mouse models for Bace1 gain- and loss-of-function need to be
generated.
For the generation of a Bace1 over-expressing mouse line, the Rosa26 knock-in plas-
mid [243] was utilised. This vector, which allows over-expression of target genes in a
Cre-dependent manner, was generated in-house via cloning of the murine Bace1 cDNA
(Bace1-LSL, Figure 6.1 a, Appendix). Validation of Bace1-LSL transfection in ES cells
was performed via SB (Figure 6.1 b) and one of the positive clones was injected in the
pro-nucleus of a fertilised egg. Unfortunately, the generated transgenic mice did not
show high levels of chimerism and none of them transmitted the genetic modification
to their progeny. For this reason, further pro-nuclear injections are needed to generate
Bace1-LSL mice.
For the generation of a conditional knock-out of Bace1, a commercially available plasmid
containing a promoter-driven cassette where exon 2 of the Bace1 gene is flanked by two
loxP sites (Bace1-flox) was utilised (Figure 6.1 c). The Bace1-flox vector generates a Cre-
dependent deletion of BACE1 using the strategy first described by Luo et al. [32], which
was also utilised for the generation of our C2C12∆Bace1 cell line (4.7). Correct transfection
of the plasmid was confirmed by SB analysis (Figure 6.1 d), however pronuclear injection
for the generation of Bace1-flox mice have not been performed yet.
Both mouse models would be very useful to further investigate the role of BACE1 in
metabolic and peripheral tissues regulation. This could be obtained via crossing of the
newly generated mouse lines with tissue specific Cre recombinase lines. Of particular
interest would be to utilise Cre recombinase in vivo lines specific for pan or brown adi-
pose tissue, namely Adipoq-Cre [244] and Ucp1-Cre [245], respectively, and for skeletal
muscle, Mck-Cre [246]. Moreover, in light of the proposed role for BACE1 in regulating
the switch between myogenesis and brown adipogenesis, Bace1-LSL and Bace-flox mice
could be crossed with Cre lines targeting the common precursors of this two lineages,
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such as Myf5-Cre and Pax3-Cre [208]. Conditional Bace1 knock-out mice should then
be exposed to HFD to investigate potential beneficial effects of β-secretase depletion in
diet-induced obesity, whereas the possible detrimental effects of Bace1 over-expression
could be investigated in a NCD condition.
To exploit the potential of peripheral BACE1 regulation in AD, the above described mouse
lines could be also crossed with the established 3xTg-AD model, which harbours three
AD-predisposing genetic lesions (APP Swedish Mutation, MAPT P301L and PSEN1
M146V) relevant for familial AD [247]. The generated in vivo models could then be
characterised to investigate the effects of peripheral BACE1 down- or up-regulation on
the pathophysiology of AD, performing behavioural tests and biochemical analysis of Aβ
deposition.
Moreover, potential substrates of BACE1 (e.g AOC3) could be tested in all the aforemen-
tioned mouse models via over-expression (in Bace1-flox mice) or inhibition (in Bace1-LSL
mice) of candidate recombinant proteins (e.g. recombinant sAOC3), to test if those rescue
the expected BACE1-dependent phenotypes.
Clinical perspectives for BACE1 inhibition
BACE1 inhibition is to date the most promising approach in clinical trials to counteract
the development and progression of AD [17]. However, no studies have been performed
on the therapeutic potential of such an approach in other diseases. Our results support
the idea that inhibition of BACE1 could have beneficial effects not only in AD patients,
but also in the pathologies associated with obesity. Indeed, BACE1 inhibition in mice
reduced body weight gain (4.6.2) and enhanced glucose tolerance and insulin sensitivity
(4.6.2). Considering the high epidemiological correlation among AD, T2D and obesity
[23], it cannot be excluded that these pathologies could share the same therapeutic
targets involved in metabolism regulation. Moreover, identification of BACE1 substrates
involved in metabolism and AD regulation could unveil new therapeutic approaches.
Targeting proteins downstream of BACE1 could avoid the deleterious effects shown for
BACE1 inhibitors in vivo [17] and could provide more specific targets to treat AD or
obesity-related disease. These substrates, that could include AOC3, whose therapeutic
function is yet to be investigated, could also be suitable biomarkers for AD. This neurode-
generative pathology to date does not have reliable biomarkers able to allow an early
detection of the disease onset without high uncertainty. Classical AD biomarkers, such
as Aβ deposition and tau phosphorylation, necessitate cerebrospinal fluid (CSF) analysis
which are invasive for the patients and do not fully represent the pathophysiology of
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AD [248]. Other circulating biomarkers on the other hand, including various miRNAs,
have only recently been proposed and further investigations iare needed to validate their
reliability [248]. AOC3, with its soluble blood-released form sAOC3, has already been
proven as AD-relevant, showing to be increased in hippocampal blood vessels and being
proposed as a therapeutic target for preventing/delaying the progress of AD-associated
vasculopathy [201] [202]. Further studies are however needed to indicate a real potential
for sAOC3 as an AD biomarker.
Taken together, BACE1 and its substrates (e.g. AOC3) can be claimed to be promising
therapeutic targets for AD, obesity and their sequelae. This warrants the broadening
of the scientific scope for BACE1 investigation beyond AD and towards brown adipose
tissue and metabolism regulation.
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APPENDIX
Table 6.1: List of CSC-detected peptides in the PI3K/AKT, FGFR and EGFR signalling pathway up-
regulated on the cell surface of C2C12∆Bace1 cells compared to wild-type C2C12. Indicated in bold are the
proteins which were validated via WB (4.9.1). FC = fold change, nd = not detectable.
Protein ID Gene name log2 FC adj. p-value
P07141 Csf1 Macrophage colony-stimulating factor 1 1,64246 0,01290
Q01279 Egfr Epidermal growth factor receptor 1,77909 0,05211
P21803 Fgfr2 Fibroblast growth factor receptor 2 4,08144 0,05003
Q03142 Fgfr4 Fibroblast growth factor receptor 4 1,12740 0,21831
P26952 Il3ra Interleukin-3 receptor subunit alpha 1,61688 0,01814
Q3V3R4 Itga1 Integrin alpha-1 4,36586 0,02246
P61622 Itga11 Integrin alpha-11 5,96986 0,03519
Q62470 Itga3 Integrin alpha-3 1,20113 0,04282
P20826 Kitlg Kit ligand nd in C2C12 nd
Q8BLG2 Lpar4 Lysophosphatidic acid receptor 4 3,29353 0,03410
Q6VVW5 Npr2 Atrial natriuretic peptide receptor 2 2,11275 0,02776
P70180 Npr3 Atrial natriuretic peptide receptor 3 2,86614 0,01935
O70458 Osmr Oncostatin-M-specific receptor subunit beta 1,41507 0,01995
P05622 Pdgfrb Platelet-derived growth factor receptor beta 1,13925 0,02288
Q9QUN7 Tlr2 Toll-like receptor 2 2,36291 0,03410
Q9QUK6 Tlr4 Toll-like receptor 4 4,15034 0,23008
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FIGURE 6.1. Generation of Bace1 gain- and loss-of-function mouse models.
a Schematic representation of Bace1-LSL (lox-STOP-lox) Rosa26 knock-in plasmid. b
Southern blot for Bace1-LSL using the ROSA26 probe (details in 2.16). The wild-type
control (WT) and a representative positive clone for each line (green boxes) are indicated.
c Schematic representation of Bace1-flox exon 2 knock-out plasmid. d Southern blot for
Bace1-flox using Bace1 exon 2 probe (details in 2.16). The wild-type control (WT) and
positive clones (green boxes) are indicated. CAG, CAG promoter; loxP, Cre recombinase
recognition site; NeoR, neomycin resistance cassette; WSS, Westphal stop sequence cas-
sette; IRES, Internal ribosome entry site; EGFP, enhanced green fluorescent protein; FRT,
Flp recombinase recognition target; En2 SA, En2 splice acceptor; lacZ, β-galactosidase
reporter; pA, polyadenylation signal; hbactP, human β-actin promoter; Bace1, Bace1 cDNA;
numbers indicate exons of Bace1.
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